EC 3.4.24.* (metalloendopeptidase) inhibitor - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	*EC 3.4.24. (metalloendopeptidase) inhibitor**	go back to main search page
Accession:	CHEBI:59107	browse the term
Definition:	Any EC 3.4.* (hydrolases acting on peptide bond) inhibitor that interferes with the activity of a metalloendopeptidase (EC 3.4.24.*).
Synonyms:	related_synonym:	EC 3.4.24.* (metalloendopeptidase) inhibitors; EC 3.4.24.* inhibitor; EC 3.4.24.* inhibitors; inhibitor of metalloendopeptidases; inhibitor of metalloendopeptidases (EC 3.4.24.); inhibitors of metalloendopeptidases; inhibitors of metalloendopeptidases (EC 3.4.24.); metalloendopeptidase inhibitors
	alt_id:	CHEBI:76786

show annotations for term's descendants Sort by:
Rat (858) Mouse (860) Human (870) Chinchilla (0) Bonobo (0) Dog (2) Squirrel (0) Pig (7) Green Monkey (0) Naked Mole-rat (0) All
Genes (858)

brazilein

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cyclin D1

decreases expression

brazilein results in decreased expression of CCND1 mRNA; brazilein results in decreased expression of CCND1 protein

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

catenin beta 1

decreases expression

brazilein results in decreased expression of CTNNB1 protein

NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111

G

glycogen synthase kinase 3 beta

decreases expression

brazilein results in decreased expression of GSK3B protein modified form

NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646

G

matrix metallopeptidase 2

multiple interactions
decreases expression

brazilein promotes the reaction [SB 203580 results in decreased expression of and results in decreased activity of MMP2 protein]; brazilein promotes the reaction [wortmannin results in decreased expression of and results in decreased activity of MMP2 protein]; brazilein results in decreased expression of and results in decreased activity of MMP2 protein; SB 203580 promotes the reaction [brazilein results in decreased expression of and results in decreased activity of MMP2 protein]; wortmannin promotes the reaction [brazilein results in decreased expression of and results in decreased activity of MMP2 protein]
brazilein results in decreased expression of MMP2 mRNA

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

NFKB inhibitor alpha

multiple interactions

brazilein results in decreased expression of and results in decreased phosphorylation of NFKBIA protein

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

RELA proto-oncogene, NF-kB subunit

decreases expression

brazilein results in decreased expression of RELA protein

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

candoxatrilat

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

membrane metallo-endopeptidase

decreases activity

candoxatrilat results in decreased activity of MME protein

NCBI chr 2:147,686,913...147,803,808
Ensembl chr 2:147,722,086...147,803,792

G

membrane metallo-endopeptidase-like 1

decreases activity

candoxatrilat results in decreased activity of MMEL1 protein

NCBI chr 5:165,431,278...165,461,716
Ensembl chr 5:165,431,343...165,461,716

G

natriuretic peptide A

multiple interactions

candoxatrilat inhibits the reaction [Carbon Tetrachloride results in decreased secretion of NPPA protein]

NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351

fluvastatin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 1

multiple interactions

[ABCA1 gene SNP co-treated with CETP gene SNP co-treated with LIPC gene SNP co-treated with LPL gene SNP] affects the susceptibility to Fluvastatin; [APOB gene SNP co-treated with APOE gene SNP co-treated with HMGCR gene SNP co-treated with LDLR gene SNP co-treated with PCSK9 gene SNP co-treated with ABCA1 gene SNP co-treated with CETP gene SNP co-treated with LIPC gene SNP co-treated with LPL gene SNP] affects the susceptibility to Fluvastatin

NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170

G

ATP binding cassette subfamily B member 11

decreases activity
multiple interactions

fluvastatin results in decreased activity of ABCB11 protein
fluvastatin inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid]

PMID:15901796 PMID:20829430

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily C member 2

affects transport
multiple interactions

ABCC2 protein affects the transport of fluvastatin
ABCC2 protein binds to and results in increased uptake of fluvastatin analog; fluvastatin analog inhibits the reaction [ABCC2 protein binds to and results in increased uptake of 5(6)-carboxy-2',7'-dichlorofluorescein]; fluvastatin promotes the reaction [ABCC2 protein results in increased export of 5(6)-carboxy-2',7'-dichlorofluorescein]

PMID:16026004 PMID:23562342 PMID:24909372

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

AKT serine/threonine kinase 1

multiple interactions

Fluvastatin inhibits the reaction [bisphenol A results in increased phosphorylation of AKT1 protein]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in increased phosphorylation of AKT1 protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in increased phosphorylation of AKT1 protein]]

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

apolipoprotein B

multiple interactions

[APOB gene SNP co-treated with APOE gene SNP co-treated with HMGCR gene SNP co-treated with LDLR gene SNP co-treated with PCSK9 gene SNP co-treated with ABCA1 gene SNP co-treated with CETP gene SNP co-treated with LIPC gene SNP co-treated with LPL gene SNP] affects the susceptibility to fluvastatin; fluvastatin promotes the reaction [[Valsartan co-treated with benazepril] results in decreased expression of APOB protein]

PMID:19773416 PMID:20671225

NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497

G

apolipoprotein E

multiple interactions
increases expression

[APOB gene SNP co-treated with APOE gene SNP co-treated with HMGCR gene SNP co-treated with LDLR gene SNP co-treated with PCSK9 gene SNP co-treated with ABCA1 gene SNP co-treated with CETP gene SNP co-treated with LIPC gene SNP co-treated with LPL gene SNP] affects the susceptibility to fluvastatin
fluvastatin results in increased expression of APOE protein

PMID:8017468 PMID:19773416

NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932

G

Rho GTPase activating protein 29

multiple interactions

[zoledronic acid co-treated with fluvastatin] results in increased expression of ARHGAP29 mRNA

NCBI chr 2:210,060,036...210,132,572
Ensembl chr 2:210,071,199...210,132,028

G

Rho guanine nucleotide exchange factor 12

multiple interactions

[zoledronic acid co-treated with fluvastatin] results in increased expression of ARHGEF12 mRNA

NCBI chr 8:43,350,070...43,475,404
Ensembl chr 8:43,353,799...43,476,366

G

Rho guanine nucleotide exchange factor 3

multiple interactions

[zoledronic acid co-treated with fluvastatin] results in increased expression of ARHGEF3 mRNA

NCBI chr16:2,301,573...2,581,951
Ensembl chr16:2,300,138...2,581,945

G

BCL2 associated X, apoptosis regulator

multiple interactions

Fluvastatin inhibits the reaction [bisphenol A results in increased expression of BAX protein]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in increased expression of BAX protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in increased expression of BAX protein]]

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

B-cell receptor-associated protein 29

multiple interactions

[zoledronic acid co-treated with fluvastatin] results in increased expression of BCAP29 mRNA

NCBI chr 6:48,182,702...48,222,698
Ensembl chr 6:48,182,706...48,222,720

G

BCL2, apoptosis regulator

multiple interactions

Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of BCL2 protein]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in decreased expression of BCL2 protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of BCL2 protein]]

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Bcl2-like 11

multiple interactions

[zoledronic acid co-treated with fluvastatin] results in increased expression of BCL2L11 mRNA

NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068

G

beclin 1

multiple interactions

Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of BECN1 protein]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in decreased expression of BECN1 protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of BECN1 protein]]

NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742

G

basic helix-loop-helix family, member e40

multiple interactions

[zoledronic acid co-treated with fluvastatin] results in increased expression of BHLHE40 mRNA

NCBI chr 4:141,618,453...141,624,154
Ensembl chr 4:141,618,476...141,624,774

G

BUB1 mitotic checkpoint serine/threonine kinase

multiple interactions

[zoledronic acid co-treated with fluvastatin] results in increased expression of BUB1 mRNA

NCBI chr 3:115,020,254...115,051,650
Ensembl chr 3:115,020,254...115,051,650

G

caspase 1

multiple interactions

[zoledronic acid co-treated with fluvastatin] results in increased expression of CASP1 mRNA

NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383

G

caspase 3

multiple interactions

fluvastatin results in increased cleavage of and results in increased activity of CASP3 protein; Mevalonic Acid inhibits the reaction [fluvastatin results in increased cleavage of and results in increased activity of CASP3 protein]
Fluvastatin inhibits the reaction [bisphenol A results in increased expression of CASP3 protein]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in increased expression of CASP3 protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in increased expression of CASP3 protein]]

PMID:24964743 PMID:35465754

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 8

increases activity
multiple interactions

fluvastatin results in increased activity of CASP8 protein
Mevalonic Acid inhibits the reaction [fluvastatin results in increased activity of CASP8 protein]

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

catalase

increases expression
multiple interactions

fluvastatin results in increased expression of CAT protein
Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of CAT protein]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in decreased expression of CAT protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of CAT protein]]

PMID:24964743 PMID:35465754

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

C-C motif chemokine ligand 2

multiple interactions

fluvastatin inhibits the reaction [Puromycin Aminonucleoside results in increased expression of CCL2 mRNA]

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

cyclin-dependent kinase 2 associated protein 2

multiple interactions

[zoledronic acid co-treated with fluvastatin] results in increased expression of CDK2AP2 mRNA

NCBI chr 1:201,391,056...201,393,137
Ensembl chr 1:201,391,466...201,393,137

G

CDC28 protein kinase regulatory subunit 2

multiple interactions

[zoledronic acid co-treated with fluvastatin] results in increased expression of CKS2 mRNA

NCBI chr17:13,570,611...13,575,770

G

cytochrome P450, family 2, subfamily b, polypeptide 3

increases expression

fluvastatin results in increased expression of CYP2B6 mRNA

NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143

G

cytochrome P450, family 3, subfamily a, polypeptide 2

decreases activity
multiple interactions

Fluvastatin results in decreased activity of CYP3A4 protein
[Fluvastatin co-treated with NR1I2 protein] results in increased expression of CYP3A4 mRNA; Fluvastatin inhibits the reaction [CYP3A4 protein affects the metabolism of Midazolam]

PMID:16029222 PMID:24204015

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

damage specific DNA binding protein 2

decreases expression
multiple interactions

fluvastatin results in decreased expression of DDB2 mRNA; fluvastatin results in decreased expression of DDB2 protein
[fluvastatin results in decreased expression of DDB2] which results in increased expression of SOD2 mRNA; Mevalonic Acid inhibits the reaction [fluvastatin results in decreased expression of DDB2 mRNA]; Mevalonic Acid inhibits the reaction [fluvastatin results in decreased expression of DDB2 protein]

NCBI chr 3:77,185,114...77,207,650
Ensembl chr 3:77,185,109...77,207,631

G

endothelin receptor type A

decreases expression

fluvastatin results in decreased expression of EDNRA mRNA

NCBI chr19:30,233,540...30,303,727
Ensembl chr19:30,233,571...30,297,049

G

epithelial membrane protein 3

multiple interactions

[zoledronic acid co-treated with fluvastatin] results in increased expression of EMP3 mRNA

NCBI chr 1:96,388,651...96,391,946
Ensembl chr 1:96,388,652...96,391,988

G

ERCC excision repair 5, endonuclease

multiple interactions

[zoledronic acid co-treated with fluvastatin] results in increased expression of ERCC5 mRNA

NCBI chr 9:46,309,477...46,354,478
Ensembl chr 9:46,309,389...46,354,472

G

ETS transcription factor ERG

multiple interactions

[zoledronic acid co-treated with fluvastatin] results in increased expression of ERG mRNA

NCBI chr11:34,678,614...34,900,951
Ensembl chr11:34,678,618...34,845,871

G

coagulation factor III, tissue factor

multiple interactions
decreases expression

Fluvastatin inhibits the reaction [Lipopolysaccharides promotes the reaction [[REL protein binds to RELA protein] which binds to F3 promoter]]; geranylgeraniol inhibits the reaction [Fluvastatin results in decreased expression of F3 protein]; Mevalonic Acid inhibits the reaction [Fluvastatin results in decreased expression of F3 mRNA]; Mevalonic Acid inhibits the reaction [Fluvastatin results in decreased expression of F3 protein]
Fluvastatin results in decreased expression of F3 mRNA; Fluvastatin results in decreased expression of F3 protein

NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668

G

farnesyl diphosphate farnesyl transferase 1

multiple interactions

[zoledronic acid co-treated with fluvastatin] results in increased expression of FDFT1 mRNA

NCBI chr15:37,412,143...37,440,198
Ensembl chr15:37,412,146...37,440,287

G

farnesyltransferase, CAAX box, subunit alpha

multiple interactions

[zoledronic acid co-treated with fluvastatin] results in increased expression of FNTA mRNA

NCBI chr16:66,065,131...66,083,460
Ensembl chr16:66,065,132...66,083,460

G

forkhead box O1

decreases phosphorylation

Fluvastatin results in decreased phosphorylation of FOXO1 protein

NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790

G

follicle stimulating hormone subunit beta

multiple interactions

Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of FSHB protein]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in decreased expression of FSHB protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of FSHB protein]]

NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370

G

glucose-6-phosphatase catalytic subunit 1

multiple interactions

[Fluvastatin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA

NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804

G

glucose-6-phosphate dehydrogenase

multiple interactions

Fluvastatin inhibits the reaction [bisphenol A results in decreased activity of G6PD protein]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in decreased activity of G6PD protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in decreased activity of G6PD protein]]

NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801

G

growth arrest and DNA-damage-inducible, beta

multiple interactions

[zoledronic acid co-treated with fluvastatin] results in increased expression of GADD45B mRNA

NCBI chr 7:8,778,004...8,780,306
Ensembl chr 7:8,778,007...8,780,046

G

glutathione-disulfide reductase

multiple interactions

Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of GSR protein]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in decreased expression of GSR protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of GSR protein]]

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

3-hydroxy-3-methylglutaryl-CoA reductase

multiple interactions
decreases activity

[APOB gene SNP co-treated with APOE gene SNP co-treated with HMGCR gene SNP co-treated with LDLR gene SNP co-treated with PCSK9 gene SNP co-treated with ABCA1 gene SNP co-treated with CETP gene SNP co-treated with LIPC gene SNP co-treated with LPL gene SNP] affects the susceptibility to fluvastatin
fluvastatin results in decreased activity of HMGCR protein

PMID:8593127 PMID:19773416

NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703

G

heme oxygenase 1

multiple interactions

Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of HMOX1 protein]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in decreased expression of HMOX1 protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of HMOX1 protein]]

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

hydroxysteroid (17-beta) dehydrogenase 1

multiple interactions

Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of HSD17B1 protein]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in decreased expression of HSD17B1 protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of HSD17B1 protein]]

NCBI chr10:86,009,728...86,011,928
Ensembl chr10:86,009,728...86,011,927

G

hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1

multiple interactions

Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of HSD3B1 protein]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in decreased expression of HSD3B1 protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of HSD3B1 protein]]

NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999

G

insulin-like growth factor 1

multiple interactions

[zoledronic acid co-treated with fluvastatin] results in increased expression of IGF1 mRNA

NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296

G

insulin-like growth factor binding protein 5

multiple interactions

[zoledronic acid co-treated with fluvastatin] results in increased expression of IGFBP5 mRNA

NCBI chr 9:74,452,371...74,464,953
Ensembl chr 9:74,448,382...74,465,156

G

interleukin 10 receptor subunit alpha

multiple interactions

[zoledronic acid co-treated with fluvastatin] results in increased expression of IL10RA mRNA

NCBI chr 8:45,563,009...45,578,041
Ensembl chr 8:45,563,137...45,578,061

G

interleukin 18

multiple interactions

Fluvastatin inhibits the reaction [bisphenol A results in increased expression of IL18 protein]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in increased expression of IL18 protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in increased expression of IL18 protein]]

NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887

G

interleukin 1 beta

decreases expression

fluvastatin results in decreased expression of IL1B mRNA

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 2 receptor subunit gamma

multiple interactions

[zoledronic acid co-treated with fluvastatin] results in increased expression of IL2RG mRNA

NCBI chr X:66,395,330...66,399,026
Ensembl chr X:66,392,542...66,399,823

G

interferon regulatory factor 4

decreases expression

Fluvastatin results in decreased expression of IRF4 protein

NCBI chr17:33,721,800...33,742,570
Ensembl chr17:33,721,811...33,740,070

G

lysine acetyltransferase 2B

multiple interactions

[zoledronic acid co-treated with fluvastatin] results in increased expression of KAT2B mRNA

NCBI chr 9:6,562,525...6,667,064
Ensembl chr 9:6,562,288...6,667,064

G

low density lipoprotein receptor

multiple interactions
increases activity

[APOB gene SNP co-treated with APOE gene SNP co-treated with HMGCR gene SNP co-treated with LDLR gene SNP co-treated with PCSK9 gene SNP co-treated with ABCA1 gene SNP co-treated with CETP gene SNP co-treated with LIPC gene SNP co-treated with LPL gene SNP] affects the susceptibility to fluvastatin; fluvastatin promotes the reaction [Cholesterol, LDL binds to LDLR protein]; fluvastatin promotes the reaction [Indomethacin promotes the reaction [Cholesterol, LDL binds to LDLR protein]]
fluvastatin results in increased activity of LDLR protein

PMID:8593127 PMID:10395027 PMID:19773416

NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580

G

luteinizing hormone subunit beta

multiple interactions

Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of LHB protein]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in decreased expression of LHB protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of LHB protein]]

NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972
Ensembl chr 1:95,900,984...95,901,972

G

lipase C, hepatic type

multiple interactions

[ABCA1 gene SNP co-treated with CETP gene SNP co-treated with LIPC gene SNP co-treated with LPL gene SNP] affects the susceptibility to fluvastatin; [APOB gene SNP co-treated with APOE gene SNP co-treated with HMGCR gene SNP co-treated with LDLR gene SNP co-treated with PCSK9 gene SNP co-treated with ABCA1 gene SNP co-treated with CETP gene SNP co-treated with LIPC gene SNP co-treated with LPL gene SNP] affects the susceptibility to fluvastatin

NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464

G

lamin A/C

decreases farnesylation

fluvastatin results in decreased farnesylation of LMNA protein

NCBI chr 2:173,939,751...173,960,423
Ensembl chr 2:173,939,751...173,960,423

G

lipoprotein lipase

multiple interactions

[ABCA1 gene SNP co-treated with CETP gene SNP co-treated with LIPC gene SNP co-treated with LPL gene SNP] affects the susceptibility to fluvastatin; [APOB gene SNP co-treated with APOE gene SNP co-treated with HMGCR gene SNP co-treated with LDLR gene SNP co-treated with PCSK9 gene SNP co-treated with ABCA1 gene SNP co-treated with CETP gene SNP co-treated with LIPC gene SNP co-treated with LPL gene SNP] affects the susceptibility to fluvastatin

NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249

G

leucine zipper tumor suppressor 1

multiple interactions

[zoledronic acid co-treated with fluvastatin] results in increased expression of LZTS1 mRNA

NCBI chr16:20,542,756...20,598,204
Ensembl chr16:20,542,809...20,598,203

G

MCL1 apoptosis regulator, BCL2 family member

decreases expression

fluvastatin results in decreased expression of MCL1 protein

NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303

G

mediator complex subunit 23

multiple interactions

[zoledronic acid co-treated with fluvastatin] results in increased expression of MED23 mRNA

NCBI chr 1:20,490,315...20,558,461
Ensembl chr 1:20,490,315...20,537,463

G

marker of proliferation Ki-67

multiple interactions

Fluvastatin inhibits the reaction [bisphenol A results in increased expression of MKI67 protein]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in increased expression of MKI67 protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in increased expression of MKI67 protein]]

NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762

G

matrix metallopeptidase 2

multiple interactions
decreases expression

Amitrole inhibits the reaction [fluvastatin results in decreased expression of MMP2 mRNA]

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

matrix metallopeptidase 9

decreases expression
multiple interactions

fluvastatin results in decreased expression of MMP9 mRNA
Amitrole inhibits the reaction [fluvastatin results in decreased expression of MMP9 mRNA]

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

M-phase phosphoprotein 8

multiple interactions

[zoledronic acid co-treated with fluvastatin] results in increased expression of MPHOSPH8 mRNA

NCBI chr15:30,800,546...30,828,415
Ensembl chr15:30,686,613...30,828,810

G

myostatin

increases expression

Fluvastatin results in increased expression of MSTN protein

NCBI chr 9:48,452,533...48,458,933
Ensembl chr 9:48,452,533...48,458,933

G

mechanistic target of rapamycin kinase

multiple interactions

Fluvastatin inhibits the reaction [bisphenol A results in increased phosphorylation of MTOR protein]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in increased phosphorylation of MTOR protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in increased phosphorylation of MTOR protein]]

NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311

G

NDC80 kinetochore complex component

multiple interactions

[zoledronic acid co-treated with fluvastatin] results in increased expression of NDC80 mRNA

NCBI chr 9:111,407,191...111,440,921
Ensembl chr 9:111,407,191...111,440,924

G

NFE2 like bZIP transcription factor 2

multiple interactions

Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of NFE2L2 protein]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in decreased expression of NFE2L2 protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of NFE2L2 protein]]

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

NLR family, pyrin domain containing 3

multiple interactions

Fluvastatin inhibits the reaction [bisphenol A results in increased expression of NLRP3 protein]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in increased expression of NLRP3 protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in increased expression of NLRP3 protein]]

NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811

G

nitric oxide synthase 2

increases expression
multiple interactions

fluvastatin results in increased expression of NOS2 mRNA; fluvastatin results in increased expression of NOS2 protein
[[fluvastatin results in increased expression of NOS2] which results in increased abundance of Nitric Oxide] which results in decreased expression of TFRC; [fluvastatin results in increased expression of NOS2] which results in increased abundance of Nitric Oxide; [N-(3-(aminomethyl)benzyl)acetamidine results in decreased activity of NOS2 protein] inhibits the reaction [fluvastatin results in increased abundance of Nitric Oxide]; Mevalonic Acid inhibits the reaction [fluvastatin results in increased expression of NOS2 protein]

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

nitric oxide synthase 3

multiple interactions

[fluvastatin co-treated with Valsartan] results in increased expression of NOS3 mRNA

NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166

G

NPHS1 adhesion molecule, nephrin

increases expression
multiple interactions

fluvastatin increases expression of Nphs1 protein in kidney
Fluvastatin inhibits the reaction [Puromycin Aminonucleoside results in decreased expression of NPHS1 mRNA]

CTD
RGD

PMID:16452496 PMID:19188342

NCBI chr 1:85,720,812...85,749,079
Ensembl chr 1:85,720,812...85,749,078

G

nuclear receptor subfamily 1, group I, member 2

increases activity
multiple interactions

fluvastatin results in increased activity of NR1I2 protein
[Fluvastatin co-treated with NR1I2 protein] results in increased expression of CYP3A4 mRNA; [Fluvastatin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA; [Fluvastatin co-treated with NR1I2 protein] results in increased expression of SGK2 mRNA

PMID:15802384 PMID:24204015

NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658

G

nuclear receptor subfamily 1, group I, member 3

increases activity

fluvastatin results in increased activity of NR1I3 protein

NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906

G

optineurin

multiple interactions

[zoledronic acid co-treated with fluvastatin] results in increased expression of OPTN mRNA

NCBI chr17:73,209,572...73,260,251
Ensembl chr17:73,209,575...73,260,251

G

protein associated with LIN7 1, MAGUK p55 family member

multiple interactions

[Zoledronic Acid co-treated with Fluvastatin] results in increased expression of PALS1 mRNA

NCBI chr 6:97,548,133...97,654,163
Ensembl chr 6:97,548,630...97,653,305

G

pappalysin 2

multiple interactions

[zoledronic acid co-treated with fluvastatin] results in increased expression of PAPPA2 mRNA

NCBI chr13:70,873,918...71,147,874
Ensembl chr13:70,876,794...71,147,779

G

proprotein convertase subtilisin/kexin type 9

multiple interactions

[APOB gene SNP co-treated with APOE gene SNP co-treated with HMGCR gene SNP co-treated with LDLR gene SNP co-treated with PCSK9 gene SNP co-treated with ABCA1 gene SNP co-treated with CETP gene SNP co-treated with LIPC gene SNP co-treated with LPL gene SNP] affects the susceptibility to fluvastatin

NCBI chr 5:121,211,278...121,233,688
Ensembl chr 5:121,211,278...121,233,688

G

paraoxonase 1

multiple interactions
decreases activity

fluvastatin inhibits the reaction [PON1 protein results in increased hydrolysis of Paraoxon]; fluvastatin inhibits the reaction [PON1 protein results in increased hydrolysis of phenylacetic acid]
fluvastatin results in decreased activity of PON1 protein

NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360

G

peroxisome proliferator activated receptor alpha

multiple interactions

fluvastatin promotes the reaction [Bezafibrate results in increased activity of [PPARA protein binds to RXRA protein]]

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

protein phosphatase 1, regulatory subunit 12A

multiple interactions

fluvastatin inhibits the reaction [Puromycin Aminonucleoside results in increased expression of PPP1R12A protein modified form]

NCBI chr 7:43,482,808...43,593,689
Ensembl chr 7:43,482,803...43,593,425

G

protein phosphatase 1, regulatory subunit 15A

multiple interactions

[zoledronic acid co-treated with fluvastatin] results in increased expression of PPP1R15A mRNA

NCBI chr 1:96,000,053...96,003,128
Ensembl chr 1:96,000,058...96,003,171

G

peroxiredoxin 3

multiple interactions

[zoledronic acid co-treated with fluvastatin] results in increased expression of PRDX3 mRNA

NCBI chr 1:260,001,642...260,014,064
Ensembl chr 1:260,001,637...260,014,111

G

protein C receptor

increases expression

fluvastatin results in increased expression of PROCR protein

NCBI chr 3:144,254,596...144,258,863
Ensembl chr 3:144,254,380...144,258,903

G

prostaglandin I2 synthase

increases expression

Fluvastatin increases expression of PTGIS mRNA in umbilical vein endothelial cells

RGD

NCBI chr 3:155,928,564...155,964,228
Ensembl chr 3:155,916,412...155,965,451

G

RAB27B, member RAS oncogene family

multiple interactions

[zoledronic acid co-treated with fluvastatin] results in increased expression of RAB27B mRNA

NCBI chr18:63,597,554...63,794,124
Ensembl chr18:63,600,937...63,757,180

G

RAB32, member RAS oncogene family

multiple interactions

[zoledronic acid co-treated with fluvastatin] results in increased expression of RAB32 mRNA

NCBI chr 1:4,946,193...4,961,003
Ensembl chr 1:4,945,036...4,960,934

G

RAB5B, member RAS oncogene family

multiple interactions

[zoledronic acid co-treated with fluvastatin] results in increased expression of RAB5B mRNA

NCBI chr 7:1,109,449...1,128,348
Ensembl chr 7:1,109,454...1,128,268

G

RAB GTPase activating protein 1-like

multiple interactions

[zoledronic acid co-treated with fluvastatin] results in increased expression of RABGAP1L mRNA

NCBI chr13:72,464,114...73,059,845
Ensembl chr13:72,468,110...73,059,984

G

RAP1A, member of RAS oncogene family

decreases prenylation

fluvastatin results in decreased prenylation of RAP1A protein

NCBI chr 2:193,208,631...193,286,513
Ensembl chr 2:193,208,635...193,286,501

G

RB transcriptional corepressor 1

decreases phosphorylation

fluvastatin results in decreased phosphorylation of RB1 protein

NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302

G

REL proto-oncogene, NF-kB subunit

multiple interactions

Fluvastatin inhibits the reaction [Lipopolysaccharides promotes the reaction [[REL protein binds to RELA protein] which binds to F3 promoter]]

NCBI chr14:97,690,105...97,721,194
Ensembl chr14:97,695,161...97,720,892

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

Fluvastatin inhibits the reaction [Lipopolysaccharides promotes the reaction [[REL protein binds to RELA protein] which binds to F3 promoter]]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

regulator of G-protein signaling 11

multiple interactions

[zoledronic acid co-treated with fluvastatin] results in increased expression of RGS11 mRNA

NCBI chr10:15,222,804...15,231,062
Ensembl chr10:15,222,803...15,231,060

G

ras homolog family member A

multiple interactions

fluvastatin inhibits the reaction [Puromycin Aminonucleoside results in increased expression of RHOA protein]

NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746

G

ras homolog family member B

multiple interactions

[zoledronic acid co-treated with fluvastatin] results in increased expression of RHOB mRNA

NCBI chr 6:31,363,752...31,365,926
Ensembl chr 6:31,363,548...31,366,108

G

regulating synaptic membrane exocytosis 2

multiple interactions

[zoledronic acid co-treated with fluvastatin] results in increased expression of RIMS2 mRNA

NCBI chr 7:70,248,104...70,759,134
Ensembl chr 7:70,243,872...70,757,491

G

Ras and Rab interactor 2

multiple interactions

[zoledronic acid co-treated with fluvastatin] results in increased expression of RIN2 mRNA

NCBI chr 3:133,086,858...133,303,604
Ensembl chr 3:133,086,749...133,303,604

G

RT1 class II, locus Ba

affects expression

fluvastatin affects the expression of HLA-DQA1 mRNA

NCBI chr20:4,575,134...4,579,727
Ensembl chr20:4,575,134...4,579,744

G

retinoid X receptor alpha

multiple interactions

fluvastatin promotes the reaction [Bezafibrate results in increased activity of [PPARA protein binds to RXRA protein]]

NCBI chr 3:10,989,832...11,076,366
Ensembl chr 3:10,989,832...11,073,712

G

serum/glucocorticoid regulated kinase 1

affects expression

fluvastatin affects the expression of SGK1 mRNA; fluvastatin affects the expression of SGK1 protein

NCBI chr 1:22,980,257...23,098,122
Ensembl chr 1:22,980,261...23,098,283

G

serum/glucocorticoid regulated kinase 2

multiple interactions

[fluvastatin co-treated with NR1I2 protein] results in increased expression of SGK2 mRNA

NCBI chr 3:151,644,102...151,669,480
Ensembl chr 3:151,644,102...151,669,480

G

solute carrier family 15 member 1

decreases activity

fluvastatin results in decreased activity of SLC15A1 protein

NCBI chr15:98,537,641...98,582,544
Ensembl chr15:98,537,641...98,582,545

G

solute carrier organic anion transporter family member 1B2

affects import

SLCO1B3 protein affects the import of fluvastatin

NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981

G

solute carrier organic anion transporter family, member 2b1

affects import

SLCO2B1 protein affects the import of Fluvastatin

NCBI chr 1:153,959,288...154,007,294
Ensembl chr 1:153,959,293...154,007,353

G

superoxide dismutase 2

multiple interactions
increases expression

[fluvastatin co-treated with Doxorubicin] results in increased expression of SOD2 protein
fluvastatin results in increased expression of SOD2 mRNA; fluvastatin results in increased expression of SOD2 protein
[fluvastatin results in decreased expression of DDB2] which results in increased expression of SOD2 mRNA; Mevalonic Acid inhibits the reaction [fluvastatin results in increased expression of SOD2 protein]

PMID:19147586 PMID:24964743

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

G

SOS Ras/Rho guanine nucleotide exchange factor 2

multiple interactions

[zoledronic acid co-treated with fluvastatin] results in increased expression of SOS2 mRNA

NCBI chr 6:88,042,966...88,156,140
Ensembl chr 6:88,042,966...88,156,692

G

spindlin family member 2A

multiple interactions

[zoledronic acid co-treated with fluvastatin] results in increased expression of SPIN2A mRNA

NCBI chr X:17,511,018...17,513,001
Ensembl chr X:17,511,022...17,513,001

G

secreted phosphoprotein 1

multiple interactions

fluvastatin inhibits the reaction [Puromycin Aminonucleoside results in increased expression of SPP1 mRNA]

NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162

G

tissue factor pathway inhibitor

increases expression

fluvastatin results in increased expression of TFPI protein

NCBI chr 3:69,533,156...69,582,547
Ensembl chr 3:69,533,156...69,576,880

G

transferrin receptor

multiple interactions
decreases expression

[[fluvastatin results in increased expression of NOS2] which results in increased abundance of Nitric Oxide] which results in decreased expression of TFRC; [fluvastatin results in decreased expression of TFRC protein] which results in decreased uptake of Iron; Amitrole inhibits the reaction [fluvastatin results in decreased expression of TFRC protein]; Mevalonic Acid inhibits the reaction [fluvastatin results in decreased expression of TFRC mRNA]; Mevalonic Acid inhibits the reaction [fluvastatin results in decreased expression of TFRC protein]; N-(3-(aminomethyl)benzyl)acetamidine inhibits the reaction [fluvastatin results in decreased expression of TFRC protein]
fluvastatin results in decreased expression of TFRC mRNA; fluvastatin results in decreased expression of TFRC protein

NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257

G

transforming growth factor, beta 1

affects expression
multiple interactions

fluvastatin affects the expression of TGFB1 protein
Fluvastatin inhibits the reaction [bisphenol A results in increased expression of TGFB1 protein]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in increased expression of TGFB1 protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in increased expression of TGFB1 protein]]

PMID:16696316 PMID:35465754

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

TNF receptor superfamily member 10b

multiple interactions

[zoledronic acid co-treated with fluvastatin] results in increased expression of TNFRSF10A mRNA

NCBI chr15:44,840,386...44,868,318
Ensembl chr15:44,840,386...44,867,467

G

tumor protein p53 inducible nuclear protein 1

multiple interactions

[zoledronic acid co-treated with fluvastatin] results in increased expression of TP53INP1 mRNA

NCBI chr 5:24,253,986...24,272,250
Ensembl chr 5:24,260,568...24,267,968

G

vimentin

multiple interactions

fluvastatin inhibits the reaction [Puromycin Aminonucleoside results in increased expression of VIM mRNA]

NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187

G

Wnt family member 11

multiple interactions

[zoledronic acid co-treated with fluvastatin] results in increased expression of WNT11 mRNA

NCBI chr 1:153,134,503...153,154,294
Ensembl chr 1:153,138,197...153,154,294

ilomastat

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

interleukin 13

multiple interactions

ilomastat inhibits the reaction [Mustard Gas results in increased expression of IL13 protein]

NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737

G

matrix metallopeptidase 1

multiple interactions

ilomastat affects the reaction [Trinitrobenzenesulfonic Acid results in increased expression of MMP1 protein]; ilomastat inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of MMP1 mRNA]

NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097

G

TIMP metallopeptidase inhibitor 1

multiple interactions

ilomastat affects the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TIMP1 mRNA]; ilomastat affects the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TIMP1 protein]

NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664

lovastatin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 1

increases expression
decreases expression
multiple interactions

Lovastatin results in increased expression of ABCA1 mRNA
lovastatin decreases expression of ABCA1 mRNA in HepG2 cells
[Dietary Fats co-treated with Lovastatin] affects the expression of ABCA1 mRNA
Lovastatin results in decreased expression of ABCA1 mRNA

CTD
RGD

PMID:19260826 PMID:29852127 PMID:27765770

NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170

G

ATP binding cassette subfamily B member 11

multiple interactions
decreases activity

Lovastatin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]
Lovastatin results in decreased activity of ABCB11 protein

PMID:23956101 PMID:24014644

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily B member 1A

multiple interactions
decreases activity
increases transport

Lovastatin analog inhibits the reaction [ABCB1 protein results in increased transport of calcein AM]
Lovastatin analog results in decreased activity of ABCB1 protein
ABCB1 protein results in increased transport of Lovastatin; ABCB1 protein results in increased transport of Lovastatin analog

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP binding cassette subfamily C member 1

decreases activity
multiple interactions

Lovastatin results in decreased activity of ABCC1 protein
[Lovastatin results in decreased activity of ABCC1 protein] which results in increased susceptibility to Antimony Sodium Gluconate; Doxorubicin inhibits the reaction [Lovastatin results in increased expression of ABCC1 mRNA]

PMID:18056276 PMID:22712078

NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114

G

ATP binding cassette subfamily C member 2

multiple interactions
increases expression
decreases activity

ABCC2 protein binds to and results in increased uptake of Lovastatin analog; Lovastatin analog inhibits the reaction [ABCC2 protein binds to and results in increased uptake of 5(6)-carboxy-2',7'-dichlorofluorescein]; Lovastatin analog inhibits the reaction [ABCC2 protein results in increased transport of calcein AM]
Lovastatin results in increased expression of ABCC2 mRNA
Lovastatin analog results in decreased activity of ABCC2 protein
ABCC2 protein binds to and results in increased uptake of Lovastatin analog; Lovastatin analog inhibits the reaction [ABCC2 protein binds to and results in increased uptake of 5(6)-carboxy-2',7'-dichlorofluorescein]; Lovastatin analog inhibits the reaction [ABCC2 protein results in increased transport of calcein AM]; Lovastatin promotes the reaction [Cisplatin results in decreased expression of ABCC2 mRNA]

PMID:15616150 PMID:23562342 PMID:26739623

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

ATP binding cassette subfamily G member 5

affects expression
multiple interactions

Lovastatin affects the expression of ABCG5 mRNA
[Dietary Fats co-treated with Lovastatin] affects the expression of ABCG5 mRNA

PMID:27208389 PMID:29852127

NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563

G

ATP binding cassette subfamily G member 8

affects expression

Lovastatin affects the expression of ABCG8 mRNA

NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912

G

acetyl-CoA carboxylase alpha

multiple interactions

[Dietary Fats co-treated with Lovastatin] affects the expression of ACACA mRNA

NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457

G

acyl-CoA oxidase 1

multiple interactions

[Dietary Fats co-treated with Lovastatin] affects the expression of ACOX1 mRNA

NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232

G

acyl-CoA synthetase short-chain family member 2

multiple interactions

[Dietary Fats co-treated with Lovastatin] affects the expression of ACSS2 mRNA

NCBI chr 3:144,003,808...144,047,452
Ensembl chr 3:144,004,336...144,059,675

G

actin alpha 2, smooth muscle

multiple interactions
decreases expression

Lovastatin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]
Lovastatin results in decreased expression of ACTA2 protein

NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554

G

actin, beta

decreases expression
increases expression

Lovastatin results in decreased expression of ACTB mRNA
Lovastatin results in increased expression of ACTB mRNA

NCBI chr12:11,663,112...11,666,697
Ensembl chr12:11,663,109...11,672,877

G

actin related protein 3

increases expression

Lovastatin results in increased expression of ACTR3 mRNA

NCBI chr13:36,800,739...36,843,837
Ensembl chr13:36,800,093...36,844,124

G

ADAM metallopeptidase domain 10

increases expression
multiple interactions

Lovastatin results in increased expression of ADAM10 protein
[Lovastatin co-treated with APP protein] results in increased expression of ADAM10 protein

NCBI chr 8:71,346,008...71,477,889
Ensembl chr 8:71,345,837...71,477,889

G

adiponectin, C1Q and collagen domain containing

affects expression
multiple interactions

Lovastatin affects the expression of ADIPOQ mRNA
[Dietary Fats co-treated with Lovastatin] affects the expression of ADIPOQ mRNA

PMID:27208389 PMID:29852127

NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564

G

adenosylhomocysteinase

decreases expression

Lovastatin results in decreased expression of AHCY mRNA

NCBI chr 3:143,569,134...143,584,359
Ensembl chr 3:143,569,094...143,584,393

G

A-kinase anchoring protein 7

decreases response to substance

AKAP7 SNP results in decreased susceptibility to Lovastatin

NCBI chr 1:20,087,190...20,217,799
Ensembl chr 1:20,087,373...20,217,797

G

AKT serine/threonine kinase 1

multiple interactions
decreases phosphorylation

Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of AKT1 protein]
Lovastatin inhibits the reaction [Cholesterol, Dietary results in decreased expression of AKT1 protein]
Lovastatin results in decreased phosphorylation of AKT1 protein

PMID:16425225 PMID:17472962 PMID:19760159 PMID:20578043 PMID:35734936

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

arachidonate 15-lipoxygenase

multiple interactions

Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased activity of ALOX15 protein]

NCBI chr10:55,060,169...55,068,885
Ensembl chr10:55,060,412...55,068,874

G

ankyrin 2

decreases response to substance

ANK2 SNP results in decreased susceptibility to Lovastatin

NCBI chr 2:215,378,028...215,954,015
Ensembl chr 2:215,379,680...215,862,923

G

annexin A4

decreases expression

Lovastatin results in decreased expression of ANXA4 mRNA

NCBI chr 4:119,184,378...119,241,183
Ensembl chr 4:119,184,374...119,241,161

G

annexin A5

decreases expression

Lovastatin results in decreased expression of ANXA5 mRNA

NCBI chr 2:119,314,007...119,344,703
Ensembl chr 2:119,314,007...119,353,369

G

apolipoprotein A1

multiple interactions

[Lovastatin co-treated with Niacin] results in increased expression of APOA1 protein; [Niacin co-treated with Lovastatin] results in increased expression of APOA1 protein

PMID:12633795 PMID:17319473

NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035

G

apolipoprotein B

multiple interactions
decreases secretion

[Niacin co-treated with Lovastatin] results in decreased expression of APOB protein
Lovastatin results in decreased secretion of APOB protein

PMID:11728391 PMID:12633795

NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497

G

apolipoprotein E

affects expression
multiple interactions

Lovastatin affects the expression of APOE mRNA
[Dietary Fats co-treated with Lovastatin] affects the expression of APOE mRNA

PMID:27208389 PMID:29852127

NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932

G

amyloid beta precursor protein

multiple interactions
increases cleavage
increases secretion

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Lovastatin results in increased secretion of APP protein modified form]; TAPI-2 inhibits the reaction [Lovastatin results in increased secretion of APP protein modified form]; U 0126 inhibits the reaction [Lovastatin results in increased secretion of APP protein]
[APP protein co-treated with Lovastatin] results in increased secretion of APP protein; [Lovastatin co-treated with APP protein] results in decreased expression of BACE1 protein; [Lovastatin co-treated with APP protein] results in increased expression of ADAM10 protein; [Lovastatin co-treated with APP protein] results in increased expression of BACE2 protein; [Lovastatin co-treated with APP protein] results in increased expression of CHRNA7 protein; [Lovastatin co-treated with APP protein] results in increased phosphorylation of MAPK1 protein; [Lovastatin co-treated with APP protein] results in increased phosphorylation of MAPK3 protein; Lovastatin affects the reaction [[MAPK1 protein co-treated with APP protein] affects the expression of APP protein]; Lovastatin affects the reaction [[MAPK1 protein co-treated with APP protein] affects the expression of CHRNA7 protein]; Lovastatin affects the reaction [[MAPK3 protein co-treated with APP protein] affects the expression of APP protein]; Lovastatin affects the reaction [[MAPK3 protein co-treated with APP protein] affects the expression of CHRNA7 protein]; U 0126 inhibits the reaction [[APP protein co-treated with Lovastatin] results in increased secretion of APP protein]; U 0126 inhibits the reaction [[Lovastatin co-treated with APP protein] results in increased expression of CHRNA7 protein]; U 0126 inhibits the reaction [[Lovastatin co-treated with APP protein] results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [[Lovastatin co-treated with APP protein] results in increased phosphorylation of MAPK3 protein]
Lovastatin results in increased cleavage of APP protein
Lovastatin results in increased secretion of APP protein; Lovastatin results in increased secretion of APP protein modified form

PMID:19741129 PMID:29341888

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

Rho GDP dissociation inhibitor alpha

increases expression

Lovastatin results in increased expression of ARHGDIA mRNA

NCBI chr10:105,854,526...105,858,020
Ensembl chr10:105,854,533...105,858,023

G

acid sensing ion channel subunit 3

increases expression

Lovastatin results in increased expression of ASIC3 mRNA

NCBI chr 4:10,760,509...10,764,987
Ensembl chr 4:10,760,597...10,764,643

G

ATM serine/threonine kinase

multiple interactions

Lovastatin inhibits the reaction [Cisplatin results in increased expression of ATM protein modified form]

NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437

G

ATR serine/threonine kinase

multiple interactions

Lovastatin inhibits the reaction [Cisplatin results in increased expression of ATR protein modified form]

NCBI chr 8:96,426,704...96,524,152
Ensembl chr 8:96,426,724...96,524,136

G

beta-secretase 1

decreases expression
multiple interactions

Lovastatin results in decreased expression of BACE1 protein
[Lovastatin co-treated with APP protein] results in decreased expression of BACE1 protein

NCBI chr 8:46,142,060...46,166,268
Ensembl chr 8:46,142,116...46,165,876

G

beta-secretase 2

multiple interactions
increases expression

[Lovastatin co-treated with APP protein] results in increased expression of BACE2 protein
Lovastatin results in increased expression of BACE2 protein

NCBI chr11:36,707,447...36,789,550
Ensembl chr11:36,707,458...36,789,546

G

BCL2 associated X, apoptosis regulator

increases expression
multiple interactions
affects localization

Lovastatin results in increased expression of BAX protein
Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of BAX protein]; Lovastatin promotes the reaction [Cisplatin results in increased expression of BAX mRNA]
Lovastatin affects the localization of BAX protein

PMID:10473109 PMID:15180944 PMID:26739623 PMID:35734936

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCAR1 scaffold protein, Cas family member

increases cleavage
multiple interactions

Lovastatin results in increased cleavage of BCAR1 protein
Mevalonic Acid inhibits the reaction [Lovastatin results in increased cleavage of BCAR1 protein]

NCBI chr19:39,679,215...39,713,907
Ensembl chr19:39,679,204...39,713,907

G

BCL2, apoptosis regulator

decreases expression
multiple interactions

Lovastatin results in decreased expression of BCL2 protein
Lovastatin inhibits the reaction [Cholesterol, Dietary results in decreased expression of BCL2 protein]; Mevalonic Acid inhibits the reaction [Lovastatin results in decreased expression of BCL2 protein]

PMID:10473109 PMID:11178870 PMID:12094262 PMID:35734936

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Bcl2-like 1

decreases expression
multiple interactions

Lovastatin results in decreased expression of BCL2L1 protein
Mevalonic Acid inhibits the reaction [Lovastatin results in decreased expression of BCL2L1 protein]

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
Ensembl chr 1:141,253,523...141,303,479

G

Bcl2-like 11

multiple interactions
increases expression

pyrazolanthrone inhibits the reaction [Lovastatin results in increased expression of BCL2L11 protein]
Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of BCL2L11 protein]

PMID:18766339 PMID:35734936

NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068

G

brain-derived neurotrophic factor

multiple interactions

Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in decreased expression of BDNF protein]

NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615

G

baculoviral IAP repeat-containing 5

multiple interactions
decreases expression

farnesyl pyrophosphate inhibits the reaction [Lovastatin results in decreased expression of BIRC5 protein]; geranylgeranyl pyrophosphate inhibits the reaction [Lovastatin results in decreased expression of BIRC5 protein]

PMID:17472962 PMID:18815881

NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380

G

BRCA2, DNA repair associated

multiple interactions

Lovastatin inhibits the reaction [Doxorubicin results in increased expression of BRCA2 mRNA]

NCBI chr12:59,492...103,789
Ensembl chr12:59,819...100,567

G

complement C1q binding protein

increases expression

Lovastatin results in increased expression of C1QBP mRNA

NCBI chr10:55,699,954...55,704,605
Ensembl chr10:55,699,954...55,704,649

G

calreticulin

increases expression

Lovastatin results in increased expression of CALR mRNA

NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414

G

calcium/calmodulin-dependent protein kinase II beta

multiple interactions

Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of CAMK2B protein]

NCBI chr14:80,845,206...80,934,172
Ensembl chr14:80,845,238...80,933,994

G

caspase 2

increases activity
multiple interactions

Lovastatin results in increased activity of CASP2 protein
Lovastatin promotes the reaction [RHOB protein binds to CASP2 protein]

PMID:12933658 PMID:16234849

NCBI chr 4:71,149,632...71,167,388
Ensembl chr 4:71,149,669...71,167,379

G

caspase 3

multiple interactions
increases cleavage
increases activity
decreases expression

farnesyl pyrophosphate inhibits the reaction [Lovastatin results in increased activity of and results in increased cleavage of CASP3 protein]; geranylgeranyl pyrophosphate inhibits the reaction [Lovastatin results in increased activity of and results in increased cleavage of CASP3 protein]
Lovastatin analog results in increased cleavage of CASP3 protein
Lovastatin results in increased activity of CASP3 protein
Lovastatin results in decreased expression of CASP3 mRNA
Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of CASP3 protein]; Lovastatin results in increased activity of and results in increased cleavage of CASP3 protein; Mevalonic Acid inhibits the reaction [Lovastatin results in increased activity of and results in increased cleavage of CASP3 protein]

PMID:11720884 PMID:12933658 PMID:15180944 PMID:16367743 PMID:18034278 More...

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 6

increases activity

Lovastatin results in increased activity of CASP6 protein

NCBI chr 2:218,466,063...218,478,503
Ensembl chr 2:218,466,076...218,478,502

G

caspase 8

increases activity

Lovastatin results in increased activity of CASP8 protein

PMID:15180944 PMID:15705602

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

caspase 9

increases activity
multiple interactions

Lovastatin results in increased activity of CASP9 protein
Lovastatin inhibits the reaction [Cholesterol, Dietary results in decreased expression of CASP9 protein]

PMID:12933658 PMID:15180944 PMID:15705602 PMID:35734936

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

catalase

multiple interactions

Lovastatin inhibits the reaction [Cholesterol, Dietary results in decreased activity of CAT protein]

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

cellular communication network factor 2

multiple interactions

Lovastatin inhibits the reaction [Doxorubicin results in increased expression of CCN2 mRNA]; Lovastatin inhibits the reaction [Epirubicin results in increased expression of CCN2 mRNA]

PMID:22712078 PMID:28710503

NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734

G

cyclin D1

decreases expression
increases expression

Lovastatin results in decreased expression of CCND1 protein
Lovastatin results in increased expression of CCND1 mRNA; Lovastatin results in increased expression of CCND1 protein

PMID:18034278 PMID:20578043

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cyclin D3

decreases expression

Lovastatin results in decreased expression of CCND3 protein

NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371

G

chaperonin containing TCP1 subunit 5

increases expression

Lovastatin results in increased expression of CCT5 mRNA

NCBI chr 2:82,591,750...82,602,903
Ensembl chr 2:82,590,630...82,602,930

G

chaperonin containing TCP1 subunit 6A

increases expression

Lovastatin results in increased expression of CCT6A mRNA

NCBI chr12:26,872,736...26,883,125
Ensembl chr12:26,872,574...26,883,337

G

chaperonin containing TCP1 subunit 8

decreases expression

Lovastatin results in decreased expression of CCT8 mRNA

NCBI chr11:26,710,370...26,722,079
Ensembl chr11:26,710,370...26,722,079

G

CD40 molecule

multiple interactions

Lovastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA]

NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534

G

CD44 molecule

decreases expression

Lovastatin results in decreased expression of CD44 mRNA; Lovastatin results in decreased expression of CD44 protein

NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620

G

cell division cycle 42

increases expression
decreases expression

Lovastatin results in increased expression of CDC42 protein
Lovastatin results in decreased expression of CDC42 mRNA

PMID:18766339 PMID:20493250

NCBI chr 5:149,555,069...149,593,239
Ensembl chr 5:149,553,724...149,593,111

G

cyclin dependent kinase 2

decreases activity

Lovastatin results in decreased activity of CDK2 protein

NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403

G

cyclin-dependent kinase 4

decreases expression

Lovastatin results in decreased expression of CDK4 mRNA; Lovastatin results in decreased expression of CDK4 protein

NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403

G

cyclin-dependent kinase 5

decreases cleavage

Lovastatin results in decreased cleavage of CDK5 protein

NCBI chr 4:10,754,682...10,760,110
Ensembl chr 4:10,754,687...10,760,112

G

cyclin-dependent kinase inhibitor 1A

increases expression
multiple interactions

Lovastatin results in increased expression of CDKN1A protein
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of CDKN1A mRNA]

PMID:18034278 PMID:22712078

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 1B

increases expression

Lovastatin results in increased expression of CDKN1B mRNA; Lovastatin results in increased expression of CDKN1B protein

PMID:9848777 PMID:10502407 PMID:15118409 PMID:18034278 PMID:20578043

NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982

G

cyclin-dependent kinase inhibitor 3

multiple interactions

Lovastatin inhibits the reaction [Cisplatin results in increased expression of CDKN3 protein modified form]

NCBI chr15:20,022,522...20,033,948
Ensembl chr15:20,022,664...20,033,945

G

centromere protein F

increases expression
multiple interactions

Lovastatin results in increased expression of CENPF protein
Lovastatin promotes the reaction [Paclitaxel results in increased expression of CENPF protein]; Mevalonic Acid inhibits the reaction [Lovastatin results in increased expression of CENPF protein]

NCBI chr13:101,184,127...101,229,714
Ensembl chr13:101,184,127...101,229,669

G

cofilin 1

decreases phosphorylation

Lovastatin results in decreased phosphorylation of CFL1 protein

NCBI chr 1:202,796,012...202,801,337
Ensembl chr 1:202,786,627...202,817,587

G

checkpoint kinase 1

multiple interactions

Lovastatin inhibits the reaction [Cisplatin results in increased phosphorylation of CHEK1 protein]; Lovastatin inhibits the reaction [Doxorubicin results in increased phosphorylation of CHEK1 protein]
Lovastatin inhibits the reaction [Cisplatin results in increased expression of CHEK1 protein modified form]

PMID:17088865 PMID:21356574 PMID:26739623

NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009

G

checkpoint kinase 2

multiple interactions

Lovastatin inhibits the reaction [Cisplatin results in increased expression of CHEK2 protein modified form]

NCBI chr12:45,788,823...45,821,382
Ensembl chr12:45,788,827...45,821,286

G

cholinergic receptor nicotinic alpha 7 subunit

multiple interactions
increases expression

[Lovastatin co-treated with APP protein] results in increased expression of CHRNA7 protein; Lovastatin affects the reaction [[MAPK1 protein co-treated with APP protein] affects the expression of CHRNA7 protein]; Lovastatin affects the reaction [[MAPK3 protein co-treated with APP protein] affects the expression of CHRNA7 protein]; U 0126 inhibits the reaction [[Lovastatin co-treated with APP protein] results in increased expression of CHRNA7 protein]
Lovastatin results in increased expression of CHRNA7 mRNA; Lovastatin results in increased expression of CHRNA7 protein
U 0126 inhibits the reaction [Lovastatin results in increased expression of CHRNA7 protein]

NCBI chr 1:116,711,559...116,837,269
Ensembl chr 1:116,714,711...116,837,240

G

chloride intracellular channel 1

decreases expression

Lovastatin results in decreased expression of CLIC1 mRNA

NCBI chr20:3,764,867...3,773,711
Ensembl chr20:3,761,461...3,773,712

G

cytochrome c oxidase subunit 5A

increases expression

Lovastatin results in increased expression of COX5A mRNA

NCBI chr 8:57,922,374...57,933,781
Ensembl chr 8:57,922,290...57,933,781

G

ceruloplasmin

multiple interactions

Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of CP protein]

NCBI chr 2:102,439,433...102,498,075
Ensembl chr 2:102,439,624...102,498,075

G

cAMP responsive element binding protein 1

multiple interactions

Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in decreased phosphorylation of CREB1 protein]

NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816

G

CRK proto-oncogene, adaptor protein

increases expression

Lovastatin results in increased expression of CRK mRNA

NCBI chr10:60,530,469...60,556,703
Ensembl chr10:60,530,464...60,553,406

G

C-reactive protein

multiple interactions

Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of CRP protein]

NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178

G

catenin beta 1

decreases degradation
increases expression
multiple interactions

Lovastatin results in decreased degradation of CTNNB1 protein
Lovastatin results in increased expression of CTNNB1 mRNA
Lovastatin affects the localization of and results in increased expression of CTNNB1 protein

PMID:17234346 PMID:19741129 PMID:24742230

NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions
increases expression

Lovastatin inhibits the reaction [Doxorubicin results in increased expression of CYP1A1 mRNA]; Lovastatin results in increased expression of and results in increased activity of CYP1A1 protein
Lovastatin results in increased expression of CYP1A1 mRNA

PMID:1311272 PMID:22712078

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily b, polypeptide 1

decreases activity

Lovastatin results in decreased activity of CYP1B1 protein

NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917

G

cytochrome P450, family 2, subfamily c, polypeptide 79

decreases activity

Lovastatin results in decreased activity of CYP2C8 protein

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions
increases expression

[Lovastatin results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA
Lovastatin results in increased expression of CYP3A4 mRNA

PMID:12505310 PMID:17041008

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

dynactin subunit 2

decreases expression

Lovastatin results in decreased expression of DCTN2 mRNA

NCBI chr 7:63,092,061...63,107,560
Ensembl chr 7:63,092,057...63,108,543

G

D-dopachrome tautomerase

decreases expression

Lovastatin results in decreased expression of DDT mRNA

NCBI chr20:12,884,216...12,886,687
Ensembl chr20:12,884,243...12,888,482

G

discs large MAGUK scaffold protein 3

multiple interactions

Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of DLG3 protein]

NCBI chr X:65,859,653...65,911,887
Ensembl chr X:65,860,172...65,910,322

G

dihydrolipoamide S-succinyltransferase

decreases expression

Lovastatin results in decreased expression of DLST mRNA

NCBI chr 6:104,758,511...104,783,296
Ensembl chr 6:104,758,631...104,783,296

G

dedicator of cytokinesis 7

increases expression

Lovastatin results in increased expression of DOCK7 mRNA

NCBI chr 5:113,599,371...113,782,871
Ensembl chr 5:113,600,198...113,782,813

G

dihydropyrimidinase-like 2

increases expression

Lovastatin results in increased expression of DPYSL2 mRNA

NCBI chr15:41,005,551...41,111,724
Ensembl chr15:41,005,551...41,111,829

G

destrin, actin depolymerizing factor

decreases expression

Lovastatin results in decreased expression of DSTN mRNA

NCBI chr 3:131,284,647...131,311,361
Ensembl chr 3:131,284,648...131,311,379

G

ELL associated factor 2

decreases response to substance

EAF2 SNP results in decreased susceptibility to Lovastatin

NCBI chr11:63,960,200...64,004,610
Ensembl chr11:63,960,200...64,004,610

G

eukaryotic translation elongation factor 2

decreases expression

Lovastatin results in decreased expression of EEF2 mRNA

NCBI chr 7:8,533,248...8,538,518
Ensembl chr 7:8,533,116...8,559,183

G

epidermal growth factor

multiple interactions

Lovastatin inhibits the reaction [EGF protein promotes the reaction [EGFR protein results in increased phosphorylation of EGFR protein]]; Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of RAF1 protein]

PMID:12942316 PMID:19760159

NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064

G

epidermal growth factor receptor

multiple interactions

Lovastatin inhibits the reaction [EGF protein promotes the reaction [EGFR protein results in increased phosphorylation of EGFR protein]]; Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]

PMID:12942316 PMID:19760159

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

eukaryotic translation initiation factor 3, subunit I

decreases expression

Lovastatin results in decreased expression of EIF3I mRNA

NCBI chr 5:141,935,135...141,942,589
Ensembl chr 5:141,935,044...141,942,676

G

ERCC excision repair 1, endonuclease non-catalytic subunit

increases expression
multiple interactions

Lovastatin results in increased expression of ERCC1 mRNA
Lovastatin promotes the reaction [Cisplatin results in increased expression of ERCC1 mRNA]

NCBI chr 1:78,971,310...79,007,963
Ensembl chr 1:78,996,390...79,007,963

G

ERCC excision repair 5, endonuclease

multiple interactions
increases expression

Lovastatin promotes the reaction [Cisplatin results in increased expression of ERCC5 mRNA]
Lovastatin results in increased expression of ERCC5 mRNA

NCBI chr 9:46,309,477...46,354,478
Ensembl chr 9:46,309,389...46,354,472

G

ERCC excision repair 6, chromatin remodeling factor

increases expression

Lovastatin results in increased expression of ERCC6 mRNA

NCBI chr16:7,764,983...7,835,587
Ensembl chr16:7,765,013...7,835,587

G

endoplasmic reticulum protein 29

decreases expression

Lovastatin results in decreased expression of ERP29 mRNA

NCBI chr12:35,089,698...35,095,952
Ensembl chr12:35,089,707...35,096,376

G

fatty acid desaturase 2

multiple interactions

[Dietary Fats co-treated with Lovastatin] affects the expression of FADS2 mRNA

NCBI chr 1:206,707,384...206,747,333
Ensembl chr 1:206,708,783...206,748,789

G

Fas cell surface death receptor

multiple interactions

Lovastatin inhibits the reaction [Doxorubicin results in increased expression of FAS mRNA]
Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of FAS protein]

PMID:17088865 PMID:35734936

NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591

G

Fas ligand

multiple interactions

Lovastatin inhibits the reaction [Doxorubicin results in increased expression of FASLG mRNA]

NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215

G

fatty acid synthase

increases expression

Lovastatin results in increased expression of FASN mRNA

NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261

G

F-box protein 32

multiple interactions
increases expression

geranylgeranyl pyrophosphate inhibits the reaction [Lovastatin results in increased expression of FBXO32 mRNA]; geranylgeranyl pyrophosphate inhibits the reaction [Lovastatin results in increased expression of FBXO32 protein]; Lovastatin promotes the reaction [Fenofibrate results in increased expression of FBXO32 protein]; Mevalonic Acid inhibits the reaction [Lovastatin results in increased expression of FBXO32 mRNA]; Mevalonic Acid inhibits the reaction [Lovastatin results in increased expression of FBXO32 protein]
Lovastatin results in increased expression of FBXO32 mRNA; Lovastatin results in increased expression of FBXO32 protein

PMID:19406843 PMID:33408297

NCBI chr 7:89,731,428...89,764,997
Ensembl chr 7:89,730,232...89,765,436

G

farnesyl diphosphate farnesyl transferase 1

increases activity

Lovastatin results in increased activity of FDFT1 protein

NCBI chr15:37,412,143...37,440,198
Ensembl chr15:37,412,146...37,440,287

G

farnesyl diphosphate synthase

multiple interactions

[Dietary Fats co-treated with Lovastatin] affects the expression of FDPS mRNA
[Cholestyramine Resin co-treated with Lovastatin] results in increased expression of FDPS mRNA; Mevalonic Acid inhibits the reaction [[Cholestyramine Resin co-treated with Lovastatin] results in increased expression of FDPS mRNA]

PMID:3670308 PMID:29852127

NCBI chr 2:174,497,402...174,507,031
Ensembl chr 2:174,486,665...174,507,776

G

flotillin 1

decreases expression

Lovastatin results in decreased expression of FLOT1 protein

NCBI chr20:2,917,864...2,927,993
Ensembl chr20:2,917,137...2,927,978

G

Fos proto-oncogene, AP-1 transcription factor subunit

affects expression
multiple interactions
decreases expression

Lovastatin affects the expression of FOS protein
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of FOS mRNA]
Lovastatin results in decreased expression of FOS

PMID:10412747 PMID:12392621 PMID:22712078

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

FosB proto-oncogene, AP-1 transcription factor subunit

multiple interactions

Lovastatin inhibits the reaction [benserazide, levodopa drug combination results in increased expression of FOSB protein]

NCBI chr 1:78,954,312...78,961,492
Ensembl chr 1:78,954,115...78,961,465

G

forkhead box O1

multiple interactions
decreases phosphorylation

Lovastatin promotes the reaction [Fenofibrate results in increased expression of FOXO1 protein]
Lovastatin results in decreased phosphorylation of FOXO1 protein

PMID:33034787 PMID:33408297

NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790

G

fascin actin-bundling protein 1

decreases expression

Lovastatin results in decreased expression of FSCN1 mRNA

NCBI chr12:11,597,042...11,610,183
Ensembl chr12:11,597,048...11,610,211

G

G3BP stress granule assembly factor 1

increases expression

Lovastatin results in increased expression of G3BP1 mRNA

NCBI chr10:39,586,864...39,620,268
Ensembl chr10:39,586,864...39,620,268

G

glucose-6-phosphate dehydrogenase

multiple interactions

[Dietary Fats co-treated with Lovastatin] affects the expression of G6PD mRNA

NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801

G

UDP-galactose-4-epimerase

decreases expression

Lovastatin results in decreased expression of GALE mRNA

NCBI chr 5:148,193,886...148,198,392
Ensembl chr 5:148,194,791...148,198,388

G

growth associated protein 43

increases expression

Lovastatin results in increased expression of GAP43 protein

NCBI chr11:58,376,371...58,470,047
Ensembl chr11:58,376,371...58,470,045

G

GDP dissociation inhibitor 2

increases expression

Lovastatin results in increased expression of GDI2 mRNA

NCBI chr17:66,649,616...66,676,299
Ensembl chr17:66,649,619...66,676,366

G

glycerol kinase

multiple interactions

[Dietary Fats co-treated with Lovastatin] affects the expression of GK mRNA

NCBI chr X:50,162,089...50,238,707
Ensembl chr X:50,163,123...50,238,631

G

guanine monophosphate synthase

increases expression

Lovastatin results in increased expression of GMPS mRNA

NCBI chr 2:148,441,369...148,491,908
Ensembl chr 2:148,435,643...148,485,875

G

glutamic--pyruvic transaminase

multiple interactions

[Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of GPT protein; Lovastatin inhibits the reaction [Dietary Fats results in increased expression of GPT protein]

PMID:29852127 PMID:30853469

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

glutathione peroxidase 1

multiple interactions

Lovastatin inhibits the reaction [Doxorubicin results in increased expression of GPX1 mRNA]

NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024

G

glutamate ionotropic receptor NMDA type subunit 2B

multiple interactions

Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of GRIN2B protein]

NCBI chr 4:168,580,824...169,044,110
Ensembl chr 4:168,599,546...169,042,279

G

glycogen synthase kinase 3 beta

decreases phosphorylation
increases phosphorylation

Lovastatin results in decreased phosphorylation of GSK3B protein
Lovastatin results in increased phosphorylation of GSK3B protein

PMID:17234346 PMID:19741129

NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646

G

H2A.X variant histone

multiple interactions

Lovastatin inhibits the reaction [Cisplatin results in increased phosphorylation of H2AX protein]
Lovastatin inhibits the reaction [Cisplatin results in increased expression of H2AX protein modified form]
Lovastatin inhibits the reaction [Cisplatin results in increased expression of H2AX protein modified form]; Lovastatin inhibits the reaction [Doxorubicin results in increased expression of H2AX protein modified form]; Lovastatin inhibits the reaction [Doxorubicin results in increased phosphorylation of H2AX protein]

PMID:21356574 PMID:22712078 PMID:26739623 PMID:28710503

NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
Ensembl chr 4:44,671,786...44,673,239

G

hyaluronan synthase 1

increases expression

Lovastatin results in increased expression of HAS1 mRNA; Lovastatin results in increased expression of HAS1 protein

NCBI chr 1:58,693,411...58,705,653
Ensembl chr 1:58,693,411...58,705,397

G

hyaluronan synthase 2

increases expression

Lovastatin results in increased expression of HAS2 mRNA

NCBI chr 7:88,113,326...88,139,337
Ensembl chr 7:88,113,326...88,128,933

G

histone deacetylase 1

increases expression

Lovastatin results in increased expression of HDAC1 mRNA

NCBI chr 5:141,853,992...141,881,057
Ensembl chr 5:141,853,989...141,881,111

G

histidine triad nucleotide binding protein 1

increases expression

Lovastatin results in increased expression of HINT1 mRNA

NCBI chr10:38,989,516...38,993,259
Ensembl chr 4:92,100,973...92,101,568

G

3-hydroxy-3-methylglutaryl-CoA reductase

multiple interactions
affects expression
decreases activity
increases expression

[Lovastatin results in decreased activity of HMGCR protein] which results in decreased abundance of farnesyl pyrophosphate; [Lovastatin results in decreased activity of HMGCR protein] which results in decreased abundance of geranylgeranyl pyrophosphate; Lovastatin inhibits the reaction [HMGCR protein results in increased abundance of geranyl diphosphate]
[Dietary Fats co-treated with Lovastatin] affects the expression of HMGCR mRNA
Lovastatin affects the expression of HMGCR mRNA
Lovastatin results in increased expression of HMGCR mRNA

PMID:8517861 PMID:8593127 PMID:17208200 PMID:19260826 PMID:19699819 More...

NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703

G

3-hydroxy-3-methylglutaryl-CoA synthase 1

multiple interactions

[Dietary Fats co-treated with Lovastatin] affects the expression of HMGCS1 mRNA

NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100

G

heme oxygenase 1

increases expression
multiple interactions

Lovastatin results in increased expression of HMOX1 protein
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of HMOX1 mRNA]

PMID:20594940 PMID:21910007 PMID:28710503

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

heterogeneous nuclear ribonucleoprotein A/B

increases expression

Lovastatin results in increased expression of HNRNPAB mRNA

NCBI chr10:35,857,040...35,862,935
Ensembl chr10:35,857,041...35,863,344

G

heterogeneous nuclear ribonucleoprotein D-like

decreases expression

Lovastatin results in decreased expression of HNRNPDL mRNA

NCBI chr14:9,557,430...9,563,659
Ensembl chr14:9,557,425...9,562,506

G

heterogeneous nuclear ribonucleoprotein F

increases expression

Lovastatin results in increased expression of HNRNPF mRNA

NCBI chr 4:151,083,262...151,104,464
Ensembl chr 4:151,083,062...151,109,038

G

heterogeneous nuclear ribonucleoprotein K

decreases expression
increases expression

Lovastatin results in decreased expression of HNRNPK mRNA
Lovastatin results in increased expression of HNRNPK mRNA

NCBI chr17:6,262,936...6,275,001
Ensembl chr17:6,262,998...6,274,997

G

HRas proto-oncogene, GTPase

decreases prenylation
multiple interactions

Lovastatin results in decreased prenylation of HRAS protein
Lovastatin results in decreased prenylation of and results in decreased localization of HRAS protein

PMID:16156861 PMID:19360310

NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615

G

heat shock protein 90 alpha family class B member 1

decreases expression

Lovastatin results in decreased expression of HSP90AB1 mRNA

NCBI chr 9:15,432,986...15,438,358
Ensembl chr 9:15,433,691...15,438,488

G

heat shock protein family A (Hsp70) member 8

increases expression

Lovastatin results in increased expression of HSPA8 mRNA

NCBI chr 8:41,183,397...41,187,260
Ensembl chr 8:41,183,264...41,187,259

G

heat shock protein family D (Hsp60) member 1

increases expression

Lovastatin results in increased expression of HSPD1 mRNA

NCBI chr 9:56,579,195...56,590,011
Ensembl chr 9:56,579,201...56,589,662

G

interferon gamma

multiple interactions

Lovastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA]

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

insulin-like growth factor 1

decreases response to substance

IGF1 protein results in decreased susceptibility to Lovastatin

NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296

G

insulin-like growth factor 1 receptor

multiple interactions

Lovastatin promotes the reaction [INS protein results in increased phosphorylation of IGF1R protein]

NCBI chr 1:121,549,831...121,838,548
Ensembl chr 1:121,550,743...121,831,777

G

interleukin 18

multiple interactions

[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL18 protein; geraniol inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL18 protein]; geraniol promotes the reaction [lonafarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL18 protein]]; geraniol promotes the reaction [manumycin inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL18 protein]]; geraniol promotes the reaction [tipifarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL18 protein]]; lonafarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL18 protein]; manumycin inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL18 protein]; tipifarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL18 protein]

NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887

G

interleukin 1 beta

multiple interactions

[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein; geraniol inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein]; geraniol promotes the reaction [lonafarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein]]; geraniol promotes the reaction [manumycin inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein]]; geraniol promotes the reaction [tipifarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein]]; lonafarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein]; Lovastatin inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; manumycin inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein]; tipifarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein]

PMID:18809656 PMID:21430599

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 24

multiple interactions

Lovastatin inhibits the reaction [Particulate Matter results in increased expression of IL24 protein]
Lovastatin inhibits the reaction [IL24 protein results in increased phosphorylation of STAT3 protein]; Lovastatin inhibits the reaction [Particulate Matter results in increased expression of and results in increased secretion of IL24 protein]; Lovastatin inhibits the reaction [Particulate Matter results in increased expression of IL24 mRNA]

NCBI chr13:42,353,089...42,358,487
Ensembl chr13:42,353,090...42,358,487

G

interleukin 6

multiple interactions

Lovastatin inhibits the reaction [Doxorubicin results in increased expression of IL6 mRNA]
Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of IL6 protein]

PMID:28710503 PMID:35734936

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

insulin 2

multiple interactions

Lovastatin promotes the reaction [INS protein results in increased phosphorylation of IGF1R protein]; Lovastatin promotes the reaction [INS protein results in increased phosphorylation of INSR protein]

NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775

G

insulin induced gene 1

increases expression
multiple interactions

Lovastatin results in increased expression of INSIG1 mRNA
[Dietary Fats co-treated with Lovastatin] affects the expression of INSIG1 mRNA

PMID:19260826 PMID:29852127

NCBI chr 4:7,315,494...7,323,972
Ensembl chr 4:7,315,495...7,323,952

G

insulin induced gene 2

multiple interactions

[Dietary Fats co-treated with Lovastatin] affects the expression of INSIG2 mRNA

NCBI chr13:32,472,390...32,500,139
Ensembl chr13:32,473,742...32,494,923

G

insulin receptor

multiple interactions

Lovastatin promotes the reaction [INS protein results in increased phosphorylation of INSR protein]

NCBI chr12:1,193,193...1,330,976
Ensembl chr12:1,197,100...1,330,883

G

importin 5

decreases expression

Lovastatin results in decreased expression of IPO5 mRNA

NCBI chr15:97,990,755...98,041,074
Ensembl chr15:98,005,299...98,041,126

G

interferon regulatory factor 4

decreases expression

Lovastatin results in decreased expression of IRF4 protein

NCBI chr17:33,721,800...33,742,570
Ensembl chr17:33,721,811...33,740,070

G

insulin receptor substrate 1

multiple interactions

[Dietary Fats co-treated with Lovastatin] affects the expression of IRS1 mRNA

NCBI chr 9:83,552,964...83,605,797
Ensembl chr 9:83,548,944...83,606,122

G

insulin receptor substrate 2

multiple interactions

[Dietary Fats co-treated with Lovastatin] affects the expression of IRS2 mRNA

NCBI chr16:78,488,249...78,512,482
Ensembl chr16:78,485,045...78,512,482

G

inositol-3-phosphate synthase 1

increases expression

Lovastatin results in increased expression of ISYNA1 mRNA

NCBI chr16:18,839,143...18,841,979
Ensembl chr16:18,839,145...18,841,979

G

integrin subunit beta 1

decreases expression

Lovastatin results in decreased expression of ITGB1 protein

NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195

G

Jun proto-oncogene, AP-1 transcription factor subunit

affects expression
multiple interactions
decreases expression

Lovastatin affects the expression of JUN protein
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of JUN mRNA]
Lovastatin results in decreased expression of JUN

PMID:10412747 PMID:12392621 PMID:22712078

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

potassium voltage-gated channel subfamily H member 2

affects activity

Lovastatin affects the activity of KCNH2 protein

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

G

potassium inwardly-rectifying channel, subfamily J, member 11

increases expression

Lovastatin results in increased expression of KCNJ11 mRNA

NCBI chr 1:96,591,048...96,594,574
Ensembl chr 1:96,591,049...96,594,082

G

KRAS proto-oncogene, GTPase

decreases prenylation
increases expression
affects localization
increases activity

Lovastatin results in decreased prenylation of KRAS protein
Lovastatin results in increased expression of KRAS protein
Lovastatin affects the localization of KRAS protein
Lovastatin results in increased activity of KRAS protein

PMID:12106604 PMID:12907238 PMID:16156861 PMID:17005160

NCBI chr 4:178,185,418...178,218,484

G

keratin 18

decreases expression

Lovastatin results in decreased expression of KRT18 mRNA

NCBI chr 7:133,157,486...133,161,162
Ensembl chr 7:133,157,475...133,161,166
Ensembl chr10:133,157,475...133,161,166

G

LIM and SH3 protein 1

decreases expression

Lovastatin results in decreased expression of LASP1 mRNA

NCBI chr10:82,795,177...82,835,659
Ensembl chr10:82,795,137...82,943,292

G

lipocalin 2

multiple interactions

[Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of LCN2 mRNA

NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095

G

lactate dehydrogenase A

increases expression

Lovastatin results in increased expression of LDHA protein

NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472

G

low density lipoprotein receptor

multiple interactions
increases activity
increases expression

OSM protein promotes the reaction [Lovastatin results in increased expression of LDLR mRNA]
[Dietary Fats co-treated with Lovastatin] affects the expression of LDLR mRNA
[Cholesterol deficiency co-treated with Lovastatin] results in increased expression of LDLR mRNA; Cholesterol inhibits the reaction [[Cholesterol deficiency co-treated with Lovastatin] results in increased expression of LDLR mRNA]
Lovastatin results in increased activity of LDLR protein

PMID:8593127 PMID:11728391 PMID:12524230 PMID:20578043 PMID:29852127

NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580

G

lymphoid enhancer binding factor 1

affects localization

Lovastatin affects the localization of LEF1 protein

NCBI chr 2:219,666,549...219,779,815
Ensembl chr 2:219,666,592...219,779,794

G

lipase C, hepatic type

affects expression

Lovastatin affects the expression of LIPC mRNA

NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464

G

lamin B1

decreases farnesylation
increases degradation
affects localization

Lovastatin results in decreased farnesylation of LMNB1 protein
Lovastatin results in increased degradation of LMNB1 protein
Lovastatin affects the localization of LMNB1 protein

PMID:10203554 PMID:11720884

NCBI chr18:50,175,861...50,215,210
Ensembl chr18:50,175,874...50,214,502

G

lipin 2

decreases response to substance

LPIN2 SNP results in decreased susceptibility to Lovastatin

NCBI chr 9:111,083,378...111,158,193
Ensembl chr 9:111,083,745...111,158,193

G

lipoprotein lipase

affects expression
multiple interactions

Lovastatin affects the expression of LPL mRNA
[Dietary Fats co-treated with Lovastatin] affects the expression of LPL mRNA

PMID:27208389 PMID:29852127

NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249

G

LDL receptor related protein 5

increases expression

Lovastatin results in increased expression of LRP5 mRNA

NCBI chr 1:200,814,247...200,917,581
Ensembl chr 1:200,814,250...200,917,581

G

mitogen activated protein kinase 1

multiple interactions
increases expression
increases phosphorylation
decreases activity
decreases phosphorylation

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Lovastatin results in decreased phosphorylation of MAPK1 protein]; 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide inhibits the reaction [Lovastatin results in decreased phosphorylation of MAPK1 protein]; Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in decreased phosphorylation of MAPK1 protein]; Lovastatin inhibits the reaction [Phenylephrine results in increased phosphorylation of MAPK1 protein]; Mevalonic Acid inhibits the reaction [Lovastatin results in decreased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Lovastatin results in increased phosphorylation of MAPK1 protein]
Lovastatin results in increased expression of MAPK1 protein
Lovastatin results in decreased activity of MAPK1 protein
[Lovastatin co-treated with APP protein] results in increased phosphorylation of MAPK1 protein; Lovastatin affects the reaction [[MAPK1 protein co-treated with APP protein] affects the expression of APP protein]; Lovastatin affects the reaction [[MAPK1 protein co-treated with APP protein] affects the expression of CHRNA7 protein]; Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [[Lovastatin co-treated with APP protein] results in increased phosphorylation of MAPK1 protein]

PMID:12213976 PMID:16952276 PMID:19360310 PMID:19760159 PMID:20578043 More...

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 14

increases expression

Lovastatin results in increased expression of MAPK14 protein

NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589

G

mitogen activated protein kinase 3

multiple interactions
increases expression
increases phosphorylation
decreases activity
decreases phosphorylation

[Lovastatin co-treated with APP protein] results in increased phosphorylation of MAPK3 protein; Lovastatin affects the reaction [[MAPK3 protein co-treated with APP protein] affects the expression of APP protein]; Lovastatin affects the reaction [[MAPK3 protein co-treated with APP protein] affects the expression of CHRNA7 protein]; Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [[Lovastatin co-treated with APP protein] results in increased phosphorylation of MAPK3 protein]
Lovastatin results in increased expression of MAPK3 protein
Lovastatin results in increased phosphorylation of MAPK3 protein
Lovastatin results in decreased activity of MAPK3 protein
Lovastatin results in decreased phosphorylation of MAPK3 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Lovastatin results in decreased phosphorylation of MAPK3 protein]; 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide inhibits the reaction [Lovastatin results in decreased phosphorylation of MAPK3 protein]; Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in decreased phosphorylation of MAPK3 protein]; Lovastatin inhibits the reaction [benserazide, levodopa drug combination results in increased phosphorylation of MAPK3 protein]; Mevalonic Acid inhibits the reaction [Lovastatin results in decreased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Lovastatin results in increased phosphorylation of MAPK3 protein]

PMID:16952276 PMID:18434508 PMID:19360310 PMID:19760159 PMID:20578043 More...

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

mitogen-activated protein kinase 8

multiple interactions

Lovastatin inhibits the reaction [Cisplatin results in increased expression of MAPK8 protein modified form]

NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981

G

mitogen-activated protein kinase 9

multiple interactions

Lovastatin inhibits the reaction [Cisplatin results in increased expression of MAPK9 protein modified form]

NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178

G

myelin basic protein

multiple interactions
increases expression

2-chloro-5-nitrobenzanilide inhibits the reaction [Lovastatin results in increased expression of MBP mRNA]; geranylgeranyl pyrophosphate inhibits the reaction [Lovastatin results in increased expression of MBP mRNA]; PPARG protein affects the reaction [Lovastatin results in increased expression of MBP mRNA]; PTEN protein affects the reaction [Lovastatin results in increased expression of MBP mRNA]

NCBI chr18:75,855,878...75,966,404
Ensembl chr18:75,855,878...75,966,404

G

mitofusin 2

multiple interactions

Lovastatin inhibits the reaction [Doxorubicin results in increased expression of MFN2 mRNA]

NCBI chr 5:158,304,285...158,335,502
Ensembl chr 5:158,304,287...158,335,342

G

microRNA 133b

multiple interactions

[Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of MIR133B mRNA

NCBI chr 9:23,098,134...23,098,217
Ensembl chr 9:23,098,134...23,098,217

G

microRNA 206

multiple interactions

[Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of MIR206 mRNA

NCBI chr 9:23,094,249...23,094,332
Ensembl chr 9:23,094,249...23,094,332

G

matrix metallopeptidase 2

decreases expression

Lovastatin results in decreased expression of MMP2 protein

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

matrix metallopeptidase 3

multiple interactions

Lovastatin inhibits the reaction [Doxorubicin results in increased expression of MMP3 mRNA]

NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961

G

matrix metallopeptidase 9

decreases expression

Lovastatin results in decreased expression of MMP9 protein

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

myeloperoxidase

multiple interactions

Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of MPO protein]

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

myostatin

increases expression

Lovastatin results in increased expression of MSTN protein

NCBI chr 9:48,452,533...48,458,933
Ensembl chr 9:48,452,533...48,458,933

G

NFE2 like bZIP transcription factor 2

multiple interactions

Doxorubicin inhibits the reaction [Lovastatin results in increased expression of NFE2L2 mRNA]; Lovastatin inhibits the reaction [Doxorubicin results in increased expression of NFE2L2 mRNA]

PMID:22712078 PMID:28710503

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

NmrA like redox sensor 1

increases expression

Lovastatin results in increased expression of NMRAL1 mRNA

NCBI chr10:10,841,693...10,850,199
Ensembl chr10:10,841,799...10,850,192

G

nitric oxide synthase 2

multiple interactions

Lovastatin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]
Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of NOS2 protein]

PMID:18809656 PMID:35734936

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

natriuretic peptide A

multiple interactions

Lovastatin inhibits the reaction [Doxorubicin results in increased expression of NPPA mRNA]

NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351

G

NAD(P)H quinone dehydrogenase 1

increases expression

Lovastatin results in increased expression of NQO1 mRNA

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

G

nuclear receptor subfamily 1, group I, member 2

multiple interactions

[Lovastatin results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA

NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658

G

NRAS proto-oncogene, GTPase

decreases prenylation

Lovastatin results in decreased prenylation of NRAS protein

NCBI chr 2:190,582,885...190,593,509
Ensembl chr 2:190,582,918...190,591,626

G

nucleobindin 1

increases expression

Lovastatin results in increased expression of NUCB1 mRNA

NCBI chr 1:95,968,325...95,999,183
Ensembl chr 1:95,968,326...96,003,220

G

ornithine aminotransferase

decreases expression

Lovastatin results in decreased expression of OAT mRNA

NCBI chr 1:187,347,862...187,367,644
Ensembl chr 1:187,347,865...187,367,682

G

oncostatin M

multiple interactions

OSM protein promotes the reaction [Lovastatin results in increased expression of LDLR mRNA]

NCBI chr14:79,103,638...79,108,500
Ensembl chr14:79,104,344...79,108,313

G

proliferation-associated 2G4

increases expression

Lovastatin results in increased expression of PA2G4 mRNA

NCBI chr 7:984,795...992,264
Ensembl chr 7:983,971...992,331

G

poly (ADP-ribose) polymerase 1

increases cleavage

Lovastatin analog results in increased cleavage of PARP1 protein

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

parvin, beta

decreases response to substance

PARVB SNP results in decreased susceptibility to Lovastatin

NCBI chr 7:115,360,254...115,445,767
Ensembl chr 7:115,360,261...115,445,766

G

phosphoenolpyruvate carboxykinase 1

multiple interactions

[Dietary Fats co-treated with Lovastatin] affects the expression of PCK1 mRNA

NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191

G

platelet derived growth factor receptor alpha

decreases expression

Lovastatin results in decreased expression of PDGFRA mRNA

NCBI chr14:33,005,838...33,054,347
Ensembl chr14:33,005,839...33,054,335

G

protein disulfide isomerase family A, member 3

decreases expression
increases expression

Lovastatin results in decreased expression of PDIA3 mRNA
Lovastatin results in increased expression of PDIA3 mRNA

NCBI chr 3:108,388,189...108,412,013
Ensembl chr 3:108,388,245...108,413,236

G

protein disulfide isomerase family A, member 4

decreases expression

Lovastatin results in decreased expression of PDIA4 mRNA

NCBI chr 4:76,803,198...76,822,245
Ensembl chr 4:76,803,198...76,822,107

G

phosphoglycerate mutase 1

decreases expression
increases expression

Lovastatin results in decreased expression of PGAM1 mRNA
Lovastatin results in increased expression of PGAM1 mRNA

NCBI chr 1:240,723,832...240,731,443
Ensembl chr 1:240,723,920...240,738,452

G

pyruvate kinase M1/2

decreases expression

Lovastatin results in decreased expression of PKM mRNA

NCBI chr 8:60,057,629...60,079,600
Ensembl chr 8:60,057,402...60,079,599

G

phospholipase A2 group 4A

increases expression

Lovastatin results in increased expression of PLA2G4A mRNA

NCBI chr13:61,877,818...62,022,261
Ensembl chr13:61,877,813...62,022,266

G

plasminogen activator, tissue type

multiple interactions
increases secretion
increases expression

geranylgeranyl pyrophosphate inhibits the reaction [Lovastatin results in increased expression of PLAT protein]; Mevalonic Acid inhibits the reaction [Lovastatin results in increased expression of PLAT protein]
Lovastatin results in increased secretion of PLAT protein

PMID:10412747 PMID:12405293

NCBI chr16:69,240,582...69,265,177
Ensembl chr16:69,240,585...69,268,223

G

plasminogen activator, urokinase

decreases secretion

Lovastatin results in decreased secretion of PLAU protein

NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775

G

paraoxonase 3

increases hydrolysis
increases metabolic processing
multiple interactions

PON3 protein results in increased hydrolysis of Lovastatin
PON3 protein results in increased metabolism of Lovastatin
7-ketocholesterol inhibits the reaction [PON3 protein results in increased metabolism of Lovastatin]; Phosphatidylcholines inhibits the reaction [PON3 protein results in increased metabolism of Lovastatin]

PMID:12615656 PMID:15772423

NCBI chr 4:33,356,983...33,383,681
Ensembl chr 4:33,349,168...33,383,855

G

peroxisome proliferator-activated receptor gamma

multiple interactions
affects localization
increases expression

2-chloro-5-nitrobenzanilide inhibits the reaction [Lovastatin analog affects the localization of PPARG protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Lovastatin analog affects the localization of PPARG protein]; PPARG protein affects the reaction [Lovastatin results in increased expression of PTEN protein]
geranylgeranyl pyrophosphate inhibits the reaction [Lovastatin results in increased expression of PPARG mRNA]; Lovastatin results in increased expression of and affects the localization of PPARG protein; Mevalonic Acid inhibits the reaction [Lovastatin results in increased expression of PPARG mRNA]; PPARG protein affects the reaction [Lovastatin results in increased expression of MBP mRNA]; PPARG protein affects the reaction [Lovastatin results in increased expression of SOX10 mRNA]
[Dietary Fats co-treated with Lovastatin] affects the expression of PPARG mRNA; PPARG affects the reaction [Lovastatin results in increased expression of PTEN protein]

PMID:16425225 PMID:20578043 PMID:26863638 PMID:29852127

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

PPARG coactivator 1 alpha

multiple interactions

Lovastatin inhibits the reaction [Doxorubicin results in increased expression of PPARGC1A mRNA]

NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656

G

protein phosphatase 1 catalytic subunit alpha

decreases expression

Lovastatin results in decreased expression of PPP1CA mRNA

NCBI chr 1:201,485,117...201,488,734
Ensembl chr 1:201,485,085...201,497,327

G

protein phosphatase 2 scaffold subunit A alpha

increases expression

Lovastatin results in increased expression of PPP2R1A mRNA

NCBI chr 1:60,540,223...60,559,467
Ensembl chr 1:60,540,194...60,560,129

G

proteoglycan 4

increases expression

Lovastatin results in increased expression of PRG4 mRNA; Lovastatin results in increased expression of PRG4 protein

NCBI chr13:62,487,257...62,504,657
Ensembl chr13:62,487,257...62,504,119

G

protein kinase C, alpha

increases expression

Lovastatin results in increased expression of PRKCA protein

NCBI chr10:92,889,390...93,288,013
Ensembl chr10:92,894,012...93,288,012

G

protein kinase C, delta

multiple interactions
increases cleavage

benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [Lovastatin results in increased cleavage of PRKCD protein]; Mevalonic Acid inhibits the reaction [Lovastatin results in increased cleavage of PRKCD protein]

NCBI chr16:5,769,217...5,799,380
Ensembl chr16:5,769,215...5,799,352

G

proteasome 20S subunit alpha 3

decreases expression

Lovastatin results in decreased expression of PSMA3 mRNA

NCBI chr 6:89,483,741...89,503,775
Ensembl chr 6:89,483,727...89,504,965

G

proteasome 20S subunit alpha 6

decreases expression

Lovastatin results in decreased expression of PSMA6 mRNA

NCBI chr 6:72,765,534...72,796,554
Ensembl chr 6:72,765,473...72,796,554

G

proteasome 26S subunit, ATPase 2

decreases expression

Lovastatin results in decreased expression of PSMC2 mRNA

NCBI chr 4:13,255,850...13,270,160
Ensembl chr 4:13,255,856...13,270,185

G

phosphatase and tensin homolog

multiple interactions
increases expression

Cycloheximide inhibits the reaction [Lovastatin results in increased expression of PTEN protein]; PPARG protein affects the reaction [Lovastatin results in increased expression of PTEN protein]
2-chloro-5-nitrobenzanilide inhibits the reaction [Lovastatin results in increased expression of PTEN mRNA]; geranylgeranyl pyrophosphate inhibits the reaction [Lovastatin results in increased expression of PTEN mRNA]; Lovastatin results in increased expression of and results in increased phosphorylation of PTEN protein; PTEN protein affects the reaction [Lovastatin results in increased expression of MBP mRNA]; PTEN protein affects the reaction [Lovastatin results in increased expression of SOX10 mRNA]
PPARG affects the reaction [Lovastatin results in increased expression of PTEN protein]

PMID:16425225 PMID:20578043

NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838

G

prostaglandin-endoperoxide synthase 2

decreases expression
increases expression
multiple interactions

Lovastatin results in decreased expression of PTGS2 protein
Lovastatin analog results in increased expression of PTGS2 mRNA; Lovastatin analog results in increased expression of PTGS2 protein
Mevalonic Acid affects the reaction [Lovastatin analog results in increased expression of PTGS2 protein]
Lovastatin results in increased expression of PTGS2 mRNA; Lovastatin results in increased expression of PTGS2 protein

PMID:20578043 PMID:21910007 PMID:26863638

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

RAB1A, member RAS oncogene family

decreases expression

Lovastatin results in decreased expression of RAB1A mRNA

NCBI chr14:94,422,219...94,448,799
Ensembl chr14:94,415,275...94,448,248

G

Rac family small GTPase 1

multiple interactions
affects localization
decreases activity
increases expression

geranylgeraniol inhibits the reaction [Lovastatin affects the localization of RAC1 protein]; Mevalonic Acid inhibits the reaction [Lovastatin affects the localization of RAC1 protein]
Lovastatin results in decreased activity of RAC1 protein
Lovastatin results in increased expression of RAC1 protein

PMID:12933658 PMID:18766339 PMID:19360310 PMID:21356574

NCBI chr12:11,037,028...11,057,251
Ensembl chr12:11,036,698...11,057,251

G

Raf-1 proto-oncogene, serine/threonine kinase

multiple interactions
decreases activity

Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of RAF1 protein]
Lovastatin results in decreased activity of RAF1 protein

PMID:19360310 PMID:19760159

NCBI chr 4:148,679,534...148,740,265
Ensembl chr 4:148,679,530...148,740,317

G

RAP1A, member of RAS oncogene family

increases expression

Lovastatin results in increased expression of RAP1A protein

NCBI chr 2:193,208,631...193,286,513
Ensembl chr 2:193,208,635...193,286,501

G

RB transcriptional corepressor 1

decreases phosphorylation

Lovastatin results in decreased phosphorylation of RB1 protein

PMID:9848777 PMID:10502407 PMID:15118409

NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302

G

ras homolog family member A

multiple interactions
decreases expression
decreases prenylation
affects localization

geranylgeraniol inhibits the reaction [Lovastatin affects the localization of RHOA protein]; Mevalonic Acid inhibits the reaction [Lovastatin affects the localization of RHOA protein]
Lovastatin results in decreased geranoylation of and affects the localization of RHOA protein
Lovastatin results in decreased expression of RHOA mRNA
Lovastatin results in decreased prenylation of RHOA protein
Farnesol inhibits the reaction [Lovastatin affects the localization of RHOA protein]; geranylgeraniol inhibits the reaction [Lovastatin affects the localization of RHOA protein]

PMID:9398081 PMID:11178870 PMID:12405293 PMID:12933658 PMID:16156861 More...

NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746

G

ras homolog family member B

decreases prenylation
multiple interactions
increases expression

Lovastatin results in decreased prenylation of RHOB protein
Lovastatin promotes the reaction [RHOB protein binds to CASP2 protein]
Lovastatin results in increased expression of RHOB protein

PMID:12467231 PMID:16156861 PMID:16234849

NCBI chr 6:31,363,752...31,365,926
Ensembl chr 6:31,363,548...31,366,108

G

ribosomal protein L27

increases expression

Lovastatin results in increased expression of RPL27 mRNA

NCBI chr10:86,375,511...86,379,210
Ensembl chr10:86,375,454...86,379,193

G

ribosomal protein L9

increases expression

Lovastatin results in increased expression of RPL9 mRNA

NCBI chr14:42,893,945...42,897,140
Ensembl chr14:42,893,942...42,897,136
Ensembl chr 3:42,893,942...42,897,136
Ensembl chr 1:42,893,942...42,897,136

G

ribosomal protein lateral stalk subunit P0

increases expression

Lovastatin results in increased expression of RPLP0 mRNA

NCBI chr12:41,054,363...41,057,632
Ensembl chr12:41,054,179...41,057,632

G

ribosomal protein SA

increases expression

Lovastatin results in increased expression of RPSA mRNA

NCBI chr 8:119,851,225...119,855,103
Ensembl chr 8:119,851,225...119,855,247

G

RuvB-like AAA ATPase 2

decreases expression

Lovastatin results in decreased expression of RUVBL2 mRNA

NCBI chr 1:95,902,014...95,915,247
Ensembl chr 1:95,901,701...95,915,342

G

S100 calcium binding protein A8

multiple interactions

[Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of S100A8 mRNA

NCBI chr 2:176,166,517...176,167,645
Ensembl chr 2:176,167,124...176,167,643

G

S100 calcium binding protein A9

multiple interactions

[Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of S100A9 mRNA

NCBI chr 2:176,190,361...176,193,182
Ensembl chr 2:176,190,361...176,193,230

G

SUMO1 activating enzyme subunit 1

decreases expression

Lovastatin results in decreased expression of SAE1 mRNA

NCBI chr 1:77,030,961...77,086,937
Ensembl chr 1:77,030,965...77,086,986

G

SREBF chaperone

multiple interactions

[Dietary Fats co-treated with Lovastatin] affects the expression of SCAP mRNA

NCBI chr 8:110,306,026...110,360,677
Ensembl chr 8:110,306,031...110,360,666

G

scavenger receptor class B, member 1

multiple interactions
affects expression

[Chloroquine co-treated with Lovastatin] inhibits the reaction [SCARB1 protein results in increased abundance of Progesterone]
Lovastatin affects the expression of SCARB1 mRNA

PMID:20404351 PMID:27208389

NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647

G

stearoyl-CoA desaturase

multiple interactions

[Dietary Fats co-treated with Lovastatin] affects the expression of SCD1 mRNA

NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562

G

selenophosphate synthetase 1

increases expression

Lovastatin results in increased expression of SEPHS1 mRNA

NCBI chr17:73,354,435...73,382,803
Ensembl chr17:73,356,530...73,382,593

G

solute carrier family 31 member 1

increases expression

Lovastatin results in increased expression of SLC31A1 mRNA

NCBI chr 5:75,814,744...75,844,241
Ensembl chr 5:75,814,743...75,844,228

G

SRY-box transcription factor 10

multiple interactions
increases expression

geranylgeranyl pyrophosphate inhibits the reaction [Lovastatin results in increased expression of SOX10 mRNA]; PPARG protein affects the reaction [Lovastatin results in increased expression of SOX10 mRNA]; PTEN protein affects the reaction [Lovastatin results in increased expression of SOX10 mRNA]

NCBI chr 7:110,725,274...110,734,651
Ensembl chr 7:110,725,274...110,735,544

G

sterol regulatory element binding transcription factor 1

multiple interactions
increases expression

[Dietary Fats co-treated with Lovastatin] affects the expression of SREBF1 mRNA
Lovastatin results in increased expression of SREBF1 mRNA

PMID:29852127 PMID:32739440

NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650

G

sterol regulatory element binding transcription factor 2

increases localization
multiple interactions

Lovastatin results in increased localization of SREBF2 protein
[Dietary Fats co-treated with Lovastatin] affects the expression of SREBF2 mRNA
[Cholesterol deficiency co-treated with Lovastatin] results in increased activity of SREBF2 protein; Cholesterol inhibits the reaction [[Cholesterol deficiency co-treated with Lovastatin] results in increased activity of SREBF2 protein]

PMID:11728391 PMID:20578043 PMID:29852127

NCBI chr 7:113,663,202...113,720,850
Ensembl chr 7:113,663,202...113,720,848

G

signal transducer and activator of transcription 3

multiple interactions

Lovastatin inhibits the reaction [IL24 protein results in increased phosphorylation of STAT3 protein]

NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057

G

STEAP2 metalloreductase

decreases response to substance

STEAP2 SNP results in decreased susceptibility to Lovastatin

NCBI chr 4:28,347,769...28,368,177
Ensembl chr 4:28,348,362...28,375,791

G

stress-induced phosphoprotein 1

decreases expression

Lovastatin results in decreased expression of STIP1 mRNA

NCBI chr 1:204,209,433...204,228,452
Ensembl chr 1:204,178,932...204,228,476

G

synaptic Ras GTPase activating protein 1

multiple interactions

Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of SYNGAP1 protein]

NCBI chr20:5,026,366...5,056,659
Ensembl chr20:5,026,364...5,056,672

G

t-complex 1

increases expression

Lovastatin results in increased expression of TCP1 mRNA

NCBI chr 1:47,829,061...47,836,809
Ensembl chr 1:47,828,652...47,836,839

G

thyroglobulin

increases secretion

Lovastatin results in increased secretion of TG protein

NCBI chr 7:98,418,293...98,603,210
Ensembl chr 7:98,418,293...98,603,210

G

transforming growth factor, beta 1

multiple interactions

Lovastatin inhibits the reaction [TGFB1 protein results in increased abundance of Reactive Oxygen Species]; Lovastatin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

tyrosine hydroxylase

increases expression
multiple interactions

Lovastatin results in increased expression of TH protein
Mevalonic Acid inhibits the reaction [Lovastatin results in increased expression of TH protein]

NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767

G

thimet oligopeptidase 1

increases expression

Lovastatin results in increased expression of THOP1 mRNA

NCBI chr 7:8,632,911...8,645,339
Ensembl chr 7:8,632,916...8,645,275

G

tumor necrosis factor

multiple interactions

[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of TNF protein; geraniol inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of TNF protein]; geraniol promotes the reaction [lonafarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of TNF protein]]; geraniol promotes the reaction [manumycin inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of TNF protein]]; geraniol promotes the reaction [tipifarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of TNF protein]]; lonafarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of TNF protein]; Lovastatin inhibits the reaction [Doxorubicin results in increased expression of TNF mRNA]; Lovastatin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Lovastatin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; manumycin inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of TNF protein]
Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of TNF protein]

PMID:18809656 PMID:21430599 PMID:22712078 PMID:35734936

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF receptor superfamily member 11B

increases expression

Lovastatin results in increased expression of TNFRSF11B mRNA

NCBI chr 7:85,566,520...85,594,526
Ensembl chr 7:85,566,520...85,594,538

G

TNF superfamily member 10

increases response to substance

Lovastatin results in increased susceptibility to TNFSF10 protein

NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135

G

TNF superfamily member 11

decreases expression

Lovastatin results in decreased expression of TNFSF11 mRNA

NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445

G

DNA topoisomerase II alpha

multiple interactions

Lovastatin inhibits the reaction [Doxorubicin results in increased expression of TOP2A mRNA]

NCBI chr10:83,945,731...83,976,874
Ensembl chr10:83,945,735...83,976,874

G

tumor protein p53

multiple interactions
increases expression

Lovastatin inhibits the reaction [Doxorubicin results in increased expression of TP53 protein]; Lovastatin results in increased expression of and results in increased phosphorylation of TP53 protein
Lovastatin inhibits the reaction [Cisplatin results in increased expression of TP53 protein modified form]
Lovastatin results in increased expression of TP53 mRNA

PMID:17088865 PMID:21199873 PMID:26739623

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

tripartite motif containing 63

multiple interactions

Lovastatin promotes the reaction [Fenofibrate results in increased expression of TRIM63 protein]

NCBI chr 5:146,533,492...146,547,332
Ensembl chr 5:146,533,507...146,547,322

G

tetratricopeptide repeat domain 7A

multiple interactions

[Dietary Fats co-treated with Lovastatin] affects the expression of FSN mRNA

NCBI chr 6:7,159,285...7,261,826
Ensembl chr 6:7,159,061...7,261,892

G

tubulin, alpha 1A

increases expression

Lovastatin results in increased expression of TUBA1A mRNA

NCBI chr 7:130,113,214...130,116,880
Ensembl chr 7:130,081,032...130,196,186

G

tubulin, alpha 1B

increases expression
decreases expression

Lovastatin results in increased expression of TUBA1B mRNA
Lovastatin results in decreased expression of TUBA1B mRNA

NCBI chr 7:130,090,663...130,093,644
Ensembl chr 7:130,081,032...130,196,186

G

tubulin, beta 5 class I

decreases expression

Lovastatin results in decreased expression of TUBB5 mRNA

NCBI chr20:2,912,779...2,916,928
Ensembl chr20:2,912,778...2,916,940

G

Tu translation elongation factor, mitochondrial

decreases expression

Lovastatin results in decreased expression of TUFM mRNA

NCBI chr 1:181,073,788...181,077,395
Ensembl chr 1:181,073,788...181,077,395

G

U2 small nuclear RNA auxiliary factor 2

increases expression

Lovastatin results in increased expression of U2AF2 mRNA

NCBI chr 1:68,760,911...68,779,730
Ensembl chr 1:68,760,924...68,778,492

G

uncoupling protein 2

multiple interactions

[Dietary Fats co-treated with Lovastatin] affects the expression of UCP2 mRNA

NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611

G

ubiquitin specific peptidase 5

decreases expression

Lovastatin results in decreased expression of USP5 mRNA

NCBI chr 4:157,619,663...157,634,681
Ensembl chr 4:157,619,643...157,634,711

G

valosin-containing protein

decreases expression
increases expression

Lovastatin results in decreased expression of VCP mRNA
Lovastatin results in increased expression of VCP mRNA

NCBI chr 5:57,210,167...57,229,571
Ensembl chr 5:57,210,168...57,229,571

G

WEE1 G2 checkpoint kinase

multiple interactions
increases expression

Lovastatin inhibits the reaction [Doxorubicin results in increased expression of WEE1 mRNA]
Lovastatin results in increased expression of WEE1 mRNA

NCBI chr 1:164,173,681...164,197,688
Ensembl chr 1:164,174,779...164,197,688

G

X-linked inhibitor of apoptosis

increases expression

Lovastatin results in increased expression of XIAP mRNA

NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700

G

XPA, DNA damage recognition and repair factor

increases expression

Lovastatin results in increased expression of XPA mRNA

NCBI chr 5:60,431,673...60,475,726
Ensembl chr 5:60,431,673...60,475,726

G

tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, epsilon

increases expression

Lovastatin results in increased expression of YWHAE mRNA

NCBI chr10:60,584,665...60,622,352
Ensembl chr10:60,584,652...60,671,589

mevastatin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetoacetyl-CoA synthetase

multiple interactions

[Cholestyramine Resin co-treated with mevastatin] results in increased expression of and results in increased activity of AACS protein; mevastatin results in increased expression of and results in increased activity of AACS protein

NCBI chr12:31,113,098...31,156,411
Ensembl chr12:31,113,098...31,160,954

G

ATP binding cassette subfamily A member 1

affects expression
decreases expression
multiple interactions

mevastatin affects the expression of ABCA1 mRNA
Mevastatin (compactin) decreases expression of abca1 mRNA in rat peripheral fibroblasts
Mevalonic Acid inhibits the reaction [mevastatin inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of ABCA1 protein]]

CTD
RGD

PMID:16415093 PMID:17526932 PMID:17526932

NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170

G

brain-derived neurotrophic factor

multiple interactions

mevastatin inhibits the reaction [BDNF protein results in decreased activity of HU 211]

NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615

G

bone morphogenetic protein 2

increases expression

mevastatin results in increased expression of BMP2 mRNA; mevastatin results in increased expression of BMP2 protein

NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397

G

CD40 molecule

multiple interactions

mevastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA]

NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions
increases expression

[mevastatin results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; NR1I2 protein promotes the reaction [mevastatin results in increased expression of CYP3A4 mRNA]

PMID:12235278 PMID:15466163 PMID:17041008

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

DNA-damage inducible transcript 3

multiple interactions
decreases expression

EIF2S1 protein modified form inhibits the reaction [mevastatin results in decreased expression of DDIT3 mRNA]

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

eukaryotic translation initiation factor 2 alpha kinase 3

increases phosphorylation

mevastatin results in increased phosphorylation of EIF2AK3 protein

NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911

G

eukaryotic translation initiation factor 2 subunit alpha

multiple interactions

EIF2S1 protein modified form inhibits the reaction [mevastatin results in decreased expression of DDIT3 mRNA]; EIF2S1 protein modified form inhibits the reaction [mevastatin results in increased cleavage of SREBF1 protein]; EIF2S1 protein modified form inhibits the reaction [mevastatin results in increased expression of IDI1 mRNA]; EIF2S1 protein modified form inhibits the reaction [mevastatin results in increased expression of MSMO1 mRNA]

NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225

G

forkhead box O1

decreases phosphorylation

mevastatin results in decreased phosphorylation of FOXO1 protein

NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790

G

isopentenyl-diphosphate delta isomerase 1

multiple interactions
increases expression

EIF2S1 protein modified form inhibits the reaction [mevastatin results in increased expression of IDI1 mRNA]

NCBI chr17:61,629,592...61,637,357
Ensembl chr17:61,629,594...61,637,357

G

interferon gamma

multiple interactions

mevastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA]

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

interleukin 1 beta

multiple interactions

mevastatin promotes the reaction [IL1B protein results in increased expression of SELE protein]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interferon regulatory factor 4

decreases expression

mevastatin results in decreased expression of IRF4 protein

NCBI chr17:33,721,800...33,742,570
Ensembl chr17:33,721,811...33,740,070

G

methylsterol monooxygenase 1

increases expression
multiple interactions

mevastatin results in increased expression of MSMO1 mRNA
EIF2S1 protein modified form inhibits the reaction [mevastatin results in increased expression of MSMO1 mRNA]

NCBI chr16:24,980,680...24,997,927
Ensembl chr16:24,980,697...24,998,016

G

myostatin

increases expression

mevastatin results in increased expression of MSTN protein

NCBI chr 9:48,452,533...48,458,933
Ensembl chr 9:48,452,533...48,458,933

G

nuclear receptor subfamily 1, group H, member 3

increases expression

Mevastatin increases expression of NR1H3 mRNA in mononuclear cells

RGD

NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722

G

nuclear receptor subfamily 1, group I, member 2

multiple interactions

[mevastatin results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; NR1I2 protein promotes the reaction [mevastatin results in increased expression of CYP3A4 mRNA]

PMID:12235278 PMID:17041008

NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658

G

Rac family small GTPase 1

multiple interactions

mevastatin results in increased abundance of [Guanosine Triphosphate binds to RAC1 protein]

NCBI chr12:11,037,028...11,057,251
Ensembl chr12:11,036,698...11,057,251

G

ras homolog family member A

decreases lipidation
multiple interactions

mevastatin results in decreased lipidation of RHOA protein
Mevalonic Acid inhibits the reaction [mevastatin results in decreased lipidation of RHOA protein]

NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746

G

selectin E

multiple interactions

mevastatin promotes the reaction [IL1B protein results in increased expression of SELE protein]; mevastatin promotes the reaction [TNF protein results in increased expression of SELE protein]

NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741

G

sterol regulatory element binding transcription factor 1

decreases expression
increases cleavage
multiple interactions

mevastatin results in decreased expression of SREBF1 protein
mevastatin results in increased cleavage of SREBF1 protein
EIF2S1 protein modified form inhibits the reaction [mevastatin results in increased cleavage of SREBF1 protein]

PMID:16330322 PMID:17526932

NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650

G

sterol regulatory element binding transcription factor 2

increases expression
increases cleavage

mevastatin results in increased expression of SREBF2 protein
mevastatin results in increased cleavage of SREBF2 protein

PMID:16330322 PMID:17526932

NCBI chr 7:113,663,202...113,720,850
Ensembl chr 7:113,663,202...113,720,848

G

tumor necrosis factor

multiple interactions

mevastatin promotes the reaction [TNF protein results in increased expression of SELE protein]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

X-box binding protein 1

multiple interactions

Tunicamycin inhibits the reaction [mevastatin results in increased cleavage of XBP1 protein]

NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693

norverapamil

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 3, subfamily a, polypeptide 9

decreases activity

norverapamil results in decreased activity of CYP3A5 protein

NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422

phosphoramidon

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensinogen

multiple interactions

phosphoramidon inhibits the reaction [AGT protein results in increased expression of EDNRA protein]

NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977

G

AKT serine/threonine kinase 1

multiple interactions

phosphoramidon inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of AKT1 protein]

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

endothelin converting enzyme 1

multiple interactions
decreases activity

EDN1 protein inhibits the reaction [phosphoramidon inhibits the reaction [Indomethacin results in increased activity of ECE1 protein]]; phosphoramidon inhibits the reaction [Indomethacin results in increased activity of ECE1 protein]; phosphoramidon inhibits the reaction [Indomethacin results in increased expression of ECE1 protein]
phosphoramidon decreases activity of recombinant Ece1 protein in COS cells

CTD
RGD

PMID:11145282 PMID:16280098 PMID:8034569

NCBI chr 5:150,077,679...150,179,375
Ensembl chr 5:150,077,644...150,179,371

G

endothelin 1

decreases expression
multiple interactions

phosphoramidon results in decreased expression of EDN1 protein
EDN1 protein inhibits the reaction [phosphoramidon inhibits the reaction [Indomethacin results in increased activity of ECE1 protein]]; EDN1 protein inhibits the reaction [phosphoramidon inhibits the reaction [Indomethacin results in increased expression of EDN1 protein]]; phosphoramidon inhibits the reaction [Indomethacin results in increased expression of EDN1 protein]

PMID:11145282 PMID:16280098 PMID:16391412

NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885

G

endothelin receptor type A

multiple interactions

phosphoramidon inhibits the reaction [AGT protein results in increased expression of EDNRA protein]; phosphoramidon inhibits the reaction [Phenylephrine results in increased expression of EDNRA protein]

NCBI chr19:30,233,540...30,303,727
Ensembl chr19:30,233,571...30,297,049

G

endothelin receptor type B

increases expression

phosphoramidon results in increased expression of EDNRB protein

NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115

G

epidermal growth factor receptor

multiple interactions

phosphoramidon inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of EGFR protein]

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

intercellular adhesion molecule 1

multiple interactions

phosphoramidon inhibits the reaction [Morphine results in decreased expression of ICAM1 protein alternative form]

NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438

G

Kell metallo-endopeptidase (Kell blood group)

multiple interactions

KEL protein alternative form binds to and affects the metabolism of phosphoramidon

NCBI chr 4:70,568,241...70,585,666
Ensembl chr 4:70,568,243...70,585,631

G

leptin

decreases expression

phosphoramidon results in decreased expression of LEP protein

NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262

G

mitogen activated protein kinase 1

multiple interactions

phosphoramidon inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions

phosphoramidon inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

membrane metallo-endopeptidase

multiple interactions

phosphoramidon inhibits the reaction [Morphine results in increased activity of MME protein]

NCBI chr 2:147,686,913...147,803,808
Ensembl chr 2:147,722,086...147,803,792

G

neurotensin

multiple interactions

phosphoramidon inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of AKT1 protein]; phosphoramidon inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of EGFR protein]; phosphoramidon inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; phosphoramidon inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]

NCBI chr 7:37,564,944...37,574,350
Ensembl chr 7:37,564,533...37,574,423

G

selectin L

multiple interactions

phosphoramidon inhibits the reaction [Morphine results in decreased expression of SELL protein alternative form]

NCBI chr13:76,416,969...76,436,444
Ensembl chr13:76,416,915...76,436,456

G

tachykinin, precursor 1

multiple interactions

[TAC1 protein co-treated with phosphoramidon] results in increased uptake of Oxygen

NCBI chr 4:35,679,183...35,687,180
Ensembl chr 4:35,679,704...35,687,178

prinomastat

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

matrix metallopeptidase 13

decreases activity

prinomastat results in decreased activity of MMP13 protein

NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239

G

matrix metallopeptidase 2

decreases activity

prinomastat results in decreased activity of MMP2 protein

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

matrix metallopeptidase 3

decreases activity

prinomastat results in decreased activity of MMP3 protein

NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961

G

matrix metallopeptidase 8

decreases activity

prinomastat results in decreased activity of MMP8 protein

NCBI chr 8:4,724,009...4,733,864
Ensembl chr 8:4,724,029...4,733,520

G

solute carrier family 22 member 2

multiple interactions

prinomastat inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268

simvastatin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

alpha-2-macroglobulin

decreases expression

Simvastatin results in decreased expression of A2M mRNA

NCBI chr 4:154,897,770...154,947,787
Ensembl chr 4:154,897,877...154,947,786

G

ATP binding cassette subfamily A member 1

decreases expression
increases expression

Simvastatin results in decreased expression of ABCA1; Simvastatin results in decreased expression of ABCA1 mRNA
Simvastatin results in increased expression of ABCA1 mRNA; Simvastatin results in increased expression of ABCA1 protein

PMID:16282522 PMID:18270459 PMID:19383813 PMID:19461118 PMID:21241519 More...

NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170

G

ATP binding cassette subfamily B member 11

multiple interactions
decreases expression
decreases activity

Simvastatin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]
Simvastatin results in decreased expression of ABCB11 mRNA
Simvastatin results in decreased activity of ABCB11 protein

PMID:20829430 PMID:23956101 PMID:24014644 PMID:27765674

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily B member 1A

multiple interactions
increases transport
decreases activity
affects response to substance

ABCB1 alternative form affects the reaction [CYP3A4 polymorphism affects the susceptibility to Simvastatin]; Simvastatin analog inhibits the reaction [ABCB1 protein results in increased transport of calcein AM]
ABCB1 protein results in increased transport of Simvastatin
Simvastatin analog results in decreased activity of ABCB1 protein
ABCB1 polymorphism affects the susceptibility to Simvastatin

PMID:15616150 PMID:16321621 PMID:19802823 PMID:19891551

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP binding cassette subfamily B member 4

increases expression
decreases expression

Simvastatin results in increased expression of ABCB4 mRNA
Simvastatin results in decreased expression of ABCB4 mRNA

PMID:21241519 PMID:27765674

NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202

G

ATP binding cassette subfamily C member 2

multiple interactions
decreases expression
affects response to substance
decreases activity

ABCC2 protein binds to and results in increased uptake of Simvastatin analog; Simvastatin analog inhibits the reaction [ABCC2 protein binds to and results in increased uptake of 5(6)-carboxy-2',7'-dichlorofluorescein]; Simvastatin analog inhibits the reaction [ABCC2 protein results in increased transport of calcein AM]
Simvastatin results in decreased expression of ABCC2 mRNA
ABCC2 polymorphism affects the susceptibility to Simvastatin
Simvastatin analog results in decreased activity of ABCC2 protein

PMID:15616150 PMID:22186618 PMID:23562342 PMID:27765674

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

ATP binding cassette subfamily C member 3

multiple interactions
increases nitrosation

artemisinin inhibits the reaction [Simvastatin results in increased nitrosation of ABCC3 protein]; parthenolide inhibits the reaction [Simvastatin results in increased nitrosation of ABCC3 protein]; Simvastatin promotes the reaction [Doxorubicin results in increased nitrosation of ABCC3 protein]

NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595

G

ATP binding cassette subfamily G member 1

decreases expression

Simvastatin results in decreased expression of ABCG1 mRNA

PMID:19383813 PMID:22120639

NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948

G

ATP binding cassette subfamily G member 5

increases expression

Simvastatin results in increased expression of ABCG5 mRNA

NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563

G

ATP binding cassette subfamily G member 8

decreases expression

Simvastatin results in decreased expression of ABCG8 mRNA

NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912

G

acetyl-CoA acyltransferase 2

decreases expression
multiple interactions

Simvastatin results in decreased expression of ACAA2 mRNA
[Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of ACAA2 mRNA

NCBI chr18:68,345,136...68,373,246
Ensembl chr18:68,345,012...68,373,249

G

acetyl-CoA carboxylase beta

increases expression

Simvastatin results in increased expression of ACACB mRNA

NCBI chr12:42,365,800...42,477,651
Ensembl chr12:42,366,548...42,457,655

G

aggrecan

multiple interactions
increases expression

Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of ACAN mRNA]; NOG inhibits the reaction [Simvastatin results in increased expression of ACAN mRNA]

PMID:18628692 PMID:19912653

NCBI chr 1:132,981,582...133,044,416
Ensembl chr 1:132,981,582...133,043,627

G

angiotensin converting enzyme 2

decreases expression

Simvastatin results in decreased expression of ACE2 mRNA

NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977

G

actin alpha 2, smooth muscle

decreases expression
multiple interactions

Simvastatin results in decreased expression of ACTA2 protein
Simvastatin inhibits the reaction [TGFB1 results in increased expression of ACTA2 mRNA]

PMID:15677772 PMID:15855201

NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554

G

actin, beta

increases expression

Simvastatin results in increased expression of ACTB mRNA

NCBI chr12:11,663,112...11,666,697
Ensembl chr12:11,663,109...11,672,877

G

actinin alpha 4

increases expression

Simvastatin results in increased expression of ACTN4 mRNA

NCBI chr 1:84,182,783...84,251,867
Ensembl chr 1:84,182,788...84,251,847

G

adiponectin, C1Q and collagen domain containing

multiple interactions

Simvastatin promotes the reaction [Lipopolysaccharides results in increased expression of ADIPOQ mRNA]; Simvastatin promotes the reaction [Lipopolysaccharides results in increased secretion of ADIPOQ protein]
carvacrol promotes the reaction [Simvastatin inhibits the reaction [Poloxamer results in decreased secretion of ADIPOQ protein]]; Simvastatin inhibits the reaction [Poloxamer results in decreased secretion of ADIPOQ protein]

PMID:17641834 PMID:29071762

NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564

G

adenosine A2B receptor

multiple interactions

Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of ADORA2B mRNA]; Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of ADORA2B protein]

NCBI chr10:46,940,394...46,956,772
Ensembl chr10:46,940,384...46,956,772

G

adrenoceptor beta 1

increases expression

Simvastatin results in increased expression of ADRB1 mRNA; Simvastatin results in increased expression of ADRB1 protein

NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259

G

alpha-fetoprotein

increases expression

Simvastatin results in increased expression of AFP mRNA

NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480

G

advanced glycosylation end product-specific receptor

multiple interactions
decreases expression

Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of AGER protein]
Simvastatin results in decreased expression of AGER protein

NCBI chr20:4,148,150...4,151,361
Ensembl chr20:4,147,890...4,151,078

G

angiotensinogen

multiple interactions
decreases expression

[Valsartan co-treated with Simvastatin] inhibits the reaction [AGT protein results in increased expression of KLF10 mRNA]; [Valsartan co-treated with Simvastatin] inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased expression of CCL2 mRNA]]; [Valsartan co-treated with Simvastatin] inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased expression of LIF mRNA]]; Simvastatin inhibits the reaction [AGT protein results in increased expression of CCL2 mRNA]; Simvastatin inhibits the reaction [AGT results in increased activity of RAC1 protein]; Simvastatin promotes the reaction [Glucose promotes the reaction [AGT protein results in increased expression of PTGS2 mRNA]]
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [AGT protein results in increased phosphorylation of PXN protein]]; Simvastatin inhibits the reaction [AGT protein results in increased phosphorylation of and affects the localization of PXN protein]; Simvastatin inhibits the reaction [CTF1 results in increased expression of AGT mRNA]
Simvastatin results in decreased expression of AGT mRNA

PMID:17513949 PMID:18400235 PMID:18475152 PMID:19100119 PMID:19225232 More...

NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977

G

angiotensin II receptor, type 1a

decreases expression

Simvastatin results in decreased expression of AGTR1 mRNA

PMID:17513949 PMID:18475152

NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946

G

aldo-keto reductase family 1, member C1

increases expression

Simvastatin results in increased expression of AKR1C1 mRNA

NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326

G

aldo-keto reductase family 1, member C3

decreases expression

Simvastatin results in decreased expression of AKR1C3 mRNA

NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873

G

aldo-keto reductase family 1, member D1

decreases expression

Simvastatin results in decreased expression of AKR1D1 mRNA

NCBI chr 4:66,154,246...66,187,505
Ensembl chr 4:66,154,248...66,186,372

G

AKT serine/threonine kinase 1

decreases expression
decreases phosphorylation
increases phosphorylation
multiple interactions
decreases activity

Simvastatin results in decreased expression of AKT1 mRNA; Simvastatin results in decreased expression of AKT1 protein
Simvastatin results in decreased phosphorylation of AKT1 protein
Simvastatin results in increased phosphorylation of AKT1 protein
farnesyl pyrophosphate inhibits the reaction [Simvastatin results in decreased phosphorylation of AKT1 protein]; FST protein inhibits the reaction [Simvastatin results in decreased phosphorylation of AKT1 protein]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased phosphorylation of AKT1 protein]; IGF1 protein inhibits the reaction [Simvastatin results in decreased phosphorylation of AKT1 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased phosphorylation of AKT1 protein]; Simvastatin inhibits the reaction [IGF1 protein results in increased phosphorylation of AKT1 protein]; Simvastatin inhibits the reaction [IGF1 results in increased activity of AKT1 protein]
Simvastatin results in decreased activity of AKT1 protein
Simvastatin inhibits the reaction [Glucose results in decreased expression of AKT1 protein modified form]; Simvastatin inhibits the reaction [Lipopolysaccharides results in decreased phosphorylation of AKT1 protein]; Simvastatin inhibits the reaction [Smoke analog results in increased phosphorylation of AKT1 protein]; Simvastatin results in increased phosphorylation of and results in increased activity of AKT1 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Nifedipine promotes the reaction [[Hydrogen Peroxide co-treated with Simvastatin] results in increased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin promotes the reaction [[Nifedipine co-treated with Hydrogen Peroxide] results in increased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin results in increased phosphorylation of and results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Simvastatin results in decreased phosphorylation of AKT1 protein]; [Hydrogen Peroxide co-treated with Simvastatin] results in increased phosphorylation of AKT1 protein; [Simvastatin co-treated with Metformin] results in decreased phosphorylation of AKT1 protein; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of AKT1 mRNA]; Nifedipine promotes the reaction [[Hydrogen Peroxide co-treated with Simvastatin] results in increased phosphorylation of AKT1 protein]; Simvastatin promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased phosphorylation of AKT1 protein]; Simvastatin promotes the reaction [[Hydrogen Peroxide co-treated with Nifedipine] results in increased phosphorylation of AKT1 protein]; Simvastatin results in increased phosphorylation of and results in increased activity of AKT1 protein; Wortmannin inhibits the reaction [Nifedipine promotes the reaction [[Hydrogen Peroxide co-treated with Simvastatin] results in increased phosphorylation of AKT1 protein]]; Wortmannin inhibits the reaction [Simvastatin promotes the reaction [[Nifedipine co-treated with Hydrogen Peroxide] results in increased phosphorylation of AKT1 protein]]

PMID:12438947 PMID:17327694 PMID:17335931 PMID:18004065 PMID:18031796 More...

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

aldehyde dehydrogenase 3 family, member A1

increases expression

Simvastatin results in increased expression of ALDH3A1 mRNA

NCBI chr10:45,892,993...45,902,680
Ensembl chr10:45,892,924...45,902,681

G

ALK receptor tyrosine kinase

multiple interactions

[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in decreased expression of ALK mRNA

NCBI chr 6:22,879,653...23,599,636
Ensembl chr 6:22,880,625...23,598,034

G

arachidonate 5-lipoxygenase activating protein

increases expression

Simvastatin results in increased expression of ALOX5AP mRNA

NCBI chr12:5,748,941...5,772,986
Ensembl chr12:5,748,944...5,772,986

G

alkaline phosphatase, intestinal

increases expression

Simvastatin results in increased expression of ALPI mRNA

NCBI chr 9:87,773,411...87,776,877
Ensembl chr 9:87,773,411...87,776,877

G

alkaline phosphatase, biomineralization associated

increases expression
multiple interactions
affects expression

Simvastatin results in increased expression of ALPL mRNA
Hydroxychloroquine affects the reaction [Simvastatin affects the expression of ALPL mRNA]

PMID:20417880 PMID:28975700

NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446

G

angiopoietin 1

increases expression

Simvastatin results in increased expression of ANGPT1; Simvastatin results in increased expression of ANGPT1 mRNA; Simvastatin results in increased expression of ANGPT1 protein

NCBI chr 7:73,528,345...73,783,953
Ensembl chr 7:73,531,486...73,784,067

G

angiopoietin 2

multiple interactions

Simvastatin inhibits the reaction [Streptozocin results in increased expression of ANGPT2 protein]

NCBI chr16:71,088,364...71,138,805
Ensembl chr16:71,088,364...71,138,804

G

angiopoietin-like 3

decreases expression

Simvastatin results in decreased expression of ANGPTL3 mRNA

NCBI chr 5:113,703,007...113,710,044
Ensembl chr 5:113,703,012...113,709,957

G

angiopoietin-like 4

increases expression

Simvastatin results in increased expression of ANGPTL4 mRNA

NCBI chr 7:14,550,288...14,557,797
Ensembl chr 7:14,550,311...14,556,519

G

ankyrin repeat family A member 2

increases expression

Simvastatin results in increased expression of ANKRA2 mRNA

NCBI chr 2:29,612,867...29,623,748
Ensembl chr 2:29,612,925...29,623,730

G

alanyl aminopeptidase, membrane

increases expression

Simvastatin results in increased expression of ANPEP mRNA

NCBI chr 1:133,767,332...133,810,137
Ensembl chr 1:133,767,332...133,785,789

G

annexin A1

increases expression

Simvastatin results in increased expression of ANXA1 protein

NCBI chr 1:217,861,175...217,877,205
Ensembl chr 1:217,861,175...217,877,343

G

annexin A3

decreases expression

Simvastatin results in decreased expression of ANXA3 mRNA
Simvastatin results in decreased expression of ANXA3 protein

PMID:14973129 PMID:17428261

NCBI chr14:12,727,708...12,781,717
Ensembl chr14:12,719,795...12,781,617

G

amine oxidase, copper containing 1

multiple interactions

Simvastatin inhibits the reaction [Oxygen deficiency results in increased expression of AOC1 mRNA]

NCBI chr 4:77,812,260...77,831,846
Ensembl chr 4:77,812,260...77,831,840

G

adipocyte plasma membrane associated protein

decreases expression

Simvastatin results in decreased expression of APMAP protein

NCBI chr 3:139,409,021...139,437,296
Ensembl chr 3:139,409,022...139,437,341

G

apolipoprotein A1

multiple interactions
decreases expression
increases expression

MTHFR gene mutant form inhibits the reaction [Simvastatin results in increased expression of APOA1 protein]
Simvastatin results in decreased expression of APOA1 mRNA; Simvastatin results in decreased expression of APOA1 protein
[Niacin co-treated with Ezetimibe co-treated with Simvastatin] results in increased expression of APOA1 protein; [Simvastatin co-treated with Ezetimibe] results in increased expression of APOA1 protein; Homocysteine inhibits the reaction [Simvastatin results in increased expression of APOA1 mRNA]; Homocysteine inhibits the reaction [Simvastatin results in increased expression of APOA1 protein]; Niacin promotes the reaction [[Simvastatin co-treated with Ezetimibe] results in increased expression of APOA1 protein]; Simvastatin results in increased expression of and results in increased secretion of APOA1 protein
Simvastatin results in increased expression of APOA1 mRNA; Simvastatin results in increased expression of APOA1 protein
Polystyrenes analog promotes the reaction [Simvastatin results in increased expression of APOA1 mRNA]; Simvastatin promotes the reaction [Polystyrenes analog results in increased expression of APOA1 mRNA]

PMID:8289597 PMID:8461338 PMID:12048122 PMID:12633795 PMID:18270459 More...

NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035

G

apolipoprotein A2

decreases expression

Simvastatin results in decreased expression of APOA2 mRNA

NCBI chr13:83,644,460...83,646,358
Ensembl chr13:83,644,470...83,646,355

G

apolipoprotein A4

multiple interactions
decreases expression
increases expression

Simvastatin inhibits the reaction [[APOA4 protein co-treated with CBS protein] affects the abundance of Nitrogen Compounds]; Simvastatin promotes the reaction [[APOA4 protein co-treated with CBS protein] affects the expression of CAV1 protein]
Simvastatin results in decreased expression of APOA4 mRNA; Simvastatin results in decreased expression of APOA4 protein
Polystyrenes analog promotes the reaction [Simvastatin results in decreased expression of APOA4 protein]; Simvastatin promotes the reaction [Polystyrenes analog results in decreased expression of APOA4 protein]
Simvastatin results in increased expression of APOA4 protein

PMID:8289597 PMID:8461338 PMID:18224302 PMID:25055962

NCBI chr 8:46,539,083...46,541,464
Ensembl chr 8:46,539,082...46,541,469

G

apolipoprotein B

multiple interactions
decreases expression
decreases secretion
affects response to substance

[LDLR 3' UTR polymorphism affects the susceptibility to Simvastatin] which affects the expression of APOB; [Niacin co-treated with Simvastatin] results in decreased expression of APOB protein; HMGCR polymorphism promotes the reaction [[LDLR 3' UTR polymorphism affects the susceptibility to Simvastatin] which affects the expression of APOB]
Simvastatin results in decreased expression of APOB protein
Simvastatin results in decreased secretion of APOB protein
Simvastatin results in decreased expression of APOB mRNA; Simvastatin results in decreased expression of APOB protein
Simvastatin promotes the reaction [Polystyrenes analog results in decreased expression of APOB protein]
APOB polymorphism affects the susceptibility to Simvastatin

PMID:1627634 PMID:8289597 PMID:8461338 PMID:9512650 PMID:10498134 More...

NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497

G

apolipoprotein C1

decreases expression

Simvastatin results in decreased expression of APOC1 mRNA

NCBI chr 1:79,347,057...79,350,340
Ensembl chr 1:79,346,136...79,350,375

G

apolipoprotein C3

decreases expression

Simvastatin results in decreased expression of APOC3 mRNA

NCBI chr 8:46,531,478...46,533,658
Ensembl chr 8:46,531,478...46,533,583

G

apolipoprotein E

decreases expression
affects response to substance
multiple interactions

Simvastatin results in decreased expression of APOE; Simvastatin results in decreased expression of APOE mRNA
Simvastatin results in decreased expression of APOE mRNA; Simvastatin results in decreased expression of APOE protein
APOE polymorphism affects the susceptibility to Simvastatin
Polystyrenes analog inhibits the reaction [Simvastatin results in decreased expression of APOE protein]
APOE affects the susceptibility to Simvastatin

PMID:8289597 PMID:8461338 PMID:11849659 PMID:11947894 PMID:12901521 More...

NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932

G

apolipoprotein F

decreases expression

Simvastatin results in decreased expression of APOF mRNA

NCBI chr 7:700,688...702,130
Ensembl chr 7:700,762...701,946

G

apolipoprotein M

decreases expression
increases expression
multiple interactions

Simvastatin results in decreased expression of APOM mRNA
Simvastatin results in increased expression of APOM mRNA; Simvastatin results in increased expression of APOM protein
T0901317 inhibits the reaction [Simvastatin results in increased expression of APOM mRNA]; T0901317 inhibits the reaction [Simvastatin results in increased expression of APOM protein]; Ursodeoxycholic Acid inhibits the reaction [Simvastatin results in increased expression of APOM mRNA]; Ursodeoxycholic Acid inhibits the reaction [Simvastatin results in increased expression of APOM protein]

PMID:21729290 PMID:22160096

NCBI chr20:3,690,950...3,693,550
Ensembl chr20:3,688,413...3,693,550

G

amyloid beta precursor protein

multiple interactions
decreases activity

oblimersen inhibits the reaction [Simvastatin results in decreased activity of APP protein alternative form]; Simvastatin inhibits the reaction [APP protein alternative form results in decreased expression of CASP3 protein]; Simvastatin inhibits the reaction [APP protein alternative form results in increased activity of CASP3 protein]
Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in increased expression of APP protein]

PMID:17241114 PMID:28734741

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

Rho GTPase activating protein 29

decreases expression

Simvastatin results in decreased expression of ARHGAP29 mRNA

NCBI chr 2:210,060,036...210,132,572
Ensembl chr 2:210,071,199...210,132,028

G

Rho GTPase activating protein 4

increases expression

Simvastatin results in increased expression of ARHGAP4 mRNA

NCBI chr X:151,636,071...151,651,528
Ensembl chr X:151,632,454...151,651,128

G

Rho/Rac guanine nucleotide exchange factor 2

increases expression

Simvastatin results in increased expression of ARHGEF2 mRNA

NCBI chr 2:174,061,126...174,118,355
Ensembl chr 2:174,062,976...174,118,355

G

argininosuccinate synthase 1

decreases expression

Simvastatin results in decreased expression of ASS1 mRNA

NCBI chr 3:14,747,355...14,796,909
Ensembl chr 3:14,747,368...14,796,903

G

activating transcription factor 2

increases phosphorylation

Simvastatin results in increased phosphorylation of ATF2 protein

NCBI chr 3:58,718,323...58,795,280
Ensembl chr 3:58,718,332...58,795,236

G

activating transcription factor 3

increases expression

Simvastatin results in increased expression of ATF3 mRNA

NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631

G

activating transcription factor 6

increases expression

Simvastatin results in increased expression of ATF6 mRNA; Simvastatin results in increased expression of ATF6 protein

NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177

G

ATM serine/threonine kinase

multiple interactions

Simvastatin results in increased phosphorylation of and results in increased activity of ATM protein

NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437

G

ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2

increases expression

Simvastatin results in increased expression of ATP2A2 mRNA; Simvastatin results in increased expression of ATP2A2 protein

NCBI chr12:34,072,710...34,122,142
Ensembl chr12:34,072,683...34,122,101

G

ATPase H+ transporting V1 subunit E1

increases expression

Simvastatin results in increased expression of ATP6V1E1 mRNA

NCBI chr 4:154,022,358...154,044,486
Ensembl chr 4:154,022,358...154,044,584

G

aurora kinase A

decreases expression

Simvastatin results in decreased expression of AURKA mRNA

NCBI chr 3:161,128,309...161,144,524
Ensembl chr 3:161,128,313...161,144,390

G

axin 2

affects expression

Simvastatin affects the expression of AXIN2 mRNA

NCBI chr10:93,893,830...93,927,042
Ensembl chr10:93,899,245...93,926,231

G

Axl receptor tyrosine kinase

decreases expression

Simvastatin results in decreased expression of AXL mRNA

NCBI chr 1:81,265,088...81,296,278
Ensembl chr 1:81,265,088...81,296,265

G

BCL2-associated agonist of cell death

multiple interactions
decreases phosphorylation

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin results in decreased phosphorylation of BAD protein]
IGF1 protein inhibits the reaction [Simvastatin results in decreased phosphorylation of BAD protein]

PMID:12438947 PMID:27734117

NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823

G

BCL2 associated X, apoptosis regulator

affects localization
increases expression

Simvastatin affects the localization of BAX protein
Simvastatin results in increased expression of BAX protein
Simvastatin results in increased expression of BAX mRNA
Simvastatin results in increased expression of BAX mRNA; Simvastatin results in increased expression of BAX protein

PMID:12557325 PMID:17901590 PMID:20045437 PMID:25300705

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

Bcl-2 binding component 3

multiple interactions
increases expression
affects localization

Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of BBC3 protein]; pifithrin inhibits the reaction [Simvastatin results in increased expression of BBC3 mRNA]; pifithrin inhibits the reaction [Simvastatin results in increased expression of BBC3 protein]
Simvastatin results in increased expression of BBC3 mRNA; Simvastatin results in increased expression of BBC3 protein
Simvastatin affects the localization of BBC3 protein

PMID:17428261 PMID:20045437 PMID:21199873 PMID:37956312

NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509

G

BCL2, apoptosis regulator

multiple interactions
decreases expression
increases expression

geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of BCL2 mRNA]; Simvastatin inhibits the reaction [TNF protein results in increased expression of BCL2 protein]; Simvastatin promotes the reaction [NFATC3 protein binds to BCL2 promoter]
Simvastatin results in decreased expression of BCL2 protein
Simvastatin results in increased expression of BCL2 mRNA; Simvastatin results in increased expression of BCL2 protein
Simvastatin results in decreased expression of BCL2 mRNA; Simvastatin results in decreased expression of BCL2 protein

PMID:17241114 PMID:17277159 PMID:17901590 PMID:18031796 PMID:18521906 More...

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Bcl2-like 1

multiple interactions
decreases expression

Simvastatin inhibits the reaction [TNF protein results in increased expression of BCL2L1 protein]
Simvastatin results in decreased expression of BCL2L1 protein

PMID:17277159 PMID:18521906 PMID:20060890

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
Ensembl chr 1:141,253,523...141,303,479

G

brain-derived neurotrophic factor

increases expression
multiple interactions

Simvastatin results in increased expression of BDNF
Simvastatin promotes the reaction [Lipopolysaccharides results in increased expression of BDNF mRNA]

PMID:18047562 PMID:20851742

NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615

G

bone gamma-carboxyglutamate protein

increases expression
multiple interactions
increases secretion

Simvastatin results in increased expression of BGLAP; Simvastatin results in increased expression of BGLAP mRNA
Simvastatin results in increased expression of BGLAP; Simvastatin results in increased expression of BGLAP mRNA; Simvastatin results in increased expression of BGLAP protein
CTNNB1 mutant form inhibits the reaction [Simvastatin results in increased expression of BGLAP protein]; DKK1 inhibits the reaction [Simvastatin results in increased expression of BGLAP mRNA]
[Simvastatin co-treated with Dexamethasone] results in increased expression of BGLAP
Simvastatin results in increased secretion of BGLAP protein

PMID:12914771 PMID:14601315 PMID:14973129 PMID:15953866 PMID:17252541 More...

NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495

G

basic helix-loop-helix family, member a15

multiple interactions

[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in decreased expression of BHLHA15 mRNA

NCBI chr12:10,420,465...10,424,641
Ensembl chr12:10,420,467...10,424,713

G

baculoviral IAP repeat-containing 2

multiple interactions
decreases expression

Simvastatin inhibits the reaction [Homocysteine results in decreased expression of BIRC2 mRNA]; Simvastatin inhibits the reaction [Homocysteine results in decreased expression of BIRC2 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of BIRC2 protein]
Simvastatin results in decreased expression of BIRC2 protein

PMID:17277159 PMID:18521906 PMID:19343037

NCBI chr 8:4,968,856...4,989,325
Ensembl chr 8:4,968,842...4,988,732

G

baculoviral IAP repeat-containing 3

multiple interactions

Simvastatin inhibits the reaction [Homocysteine results in decreased expression of BIRC3 mRNA]; Simvastatin inhibits the reaction [Homocysteine results in decreased expression of BIRC3 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of BIRC3 protein]

PMID:17277159 PMID:19343037

NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802

G

baculoviral IAP repeat-containing 5

multiple interactions
decreases expression

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Simvastatin results in decreased expression of BIRC5 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of BIRC5 protein]; Simvastatin promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of BIRC5 protein]
Simvastatin results in decreased expression of BIRC5 mRNA; Simvastatin results in decreased expression of BIRC5 protein

PMID:17277159 PMID:20464445

NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380

G

bone morphogenetic protein 1

increases expression

Simvastatin results in increased expression of BMP1 mRNA

NCBI chr15:45,551,603...45,595,862
Ensembl chr15:45,551,603...45,595,776

G

bone morphogenetic protein 2

increases secretion
increases expression
multiple interactions

Simvastatin results in increased secretion of BMP2 protein
Simvastatin results in increased expression of BMP2 mRNA; Simvastatin results in increased expression of BMP2 protein
Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of BMP2 mRNA]
Simvastatin results in increased expression of BMP2; Simvastatin results in increased expression of BMP2 mRNA
farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF protein inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF protein inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]]]; Simvastatin inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]; Simvastatin inhibits the reaction [TNF inhibits the reaction [BMP2 results in increased phosphorylation of SMAD1 protein]]; Simvastatin inhibits the reaction [TNF inhibits the reaction [BMP2 results in increased phosphorylation of SMAD5 protein]]; Simvastatin inhibits the reaction [TNF inhibits the reaction [BMP2 results in increased phosphorylation of SMAD9 protein]]; Simvastatin inhibits the reaction [TNF protein inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]]

PMID:10814523 PMID:11162604 PMID:12914771 PMID:16470222 PMID:17252541 More...

NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397

G

bone morphogenetic protein receptor type 2

affects expression
increases stability
increases expression

Simvastatin affects the expression of BMPR2 mRNA
Simvastatin results in increased stability of BMPR2 mRNA
Simvastatin results in increased expression of BMPR2 protein

NCBI chr 9:61,192,718...61,307,280
Ensembl chr 9:61,190,566...61,301,809

G

BCL2 interacting protein 3

increases expression

Simvastatin results in increased expression of BNIP3 mRNA

NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359

G

complement C5a receptor 1

decreases expression

Simvastatin results in decreased expression of C5AR1 mRNA

NCBI chr 1:76,948,622...76,959,826

G

calcium voltage-gated channel subunit alpha1 C

multiple interactions
decreases expression

Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CACNA1C mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CACNA1C protein]
Simvastatin results in decreased expression of CACNA1C mRNA; Simvastatin results in decreased expression of CACNA1C protein

NCBI chr 4:151,764,138...152,379,454
Ensembl chr 4:151,764,138...152,379,648

G

calcium voltage-gated channel subunit alpha1 H

multiple interactions
decreases expression

Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CACNA1H mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CACNA1H protein]
Simvastatin results in decreased expression of CACNA1H mRNA; Simvastatin results in decreased expression of CACNA1H protein

NCBI chr10:14,390,104...14,448,204
Ensembl chr10:14,390,113...14,448,376

G

calbindin 1

multiple interactions

Simvastatin inhibits the reaction [Oxygen deficiency results in decreased expression of CALB1 mRNA]

NCBI chr 5:29,375,624...29,402,532
Ensembl chr 5:29,375,642...29,402,431

G

calbindin 2

decreases expression

Simvastatin results in decreased expression of CALB2 protein

NCBI chr19:38,114,435...38,141,438
Ensembl chr19:38,114,424...38,141,438

G

caldesmon 1

decreases expression

Simvastatin results in decreased expression of CALD1 mRNA; Simvastatin results in decreased expression of CALD1 protein

NCBI chr 4:63,265,781...63,446,938
Ensembl chr 4:63,265,942...63,446,932

G

calmodulin-like 3

increases expression

Simvastatin results in increased expression of CALML3 mRNA

NCBI chr17:66,419,844...66,423,083
Ensembl chr17:66,419,882...66,423,175

G

calpain 1

increases expression

Simvastatin results in increased expression of CAPN1 mRNA

PMID:18664198 PMID:19253821

NCBI chr 1:203,275,912...203,300,848
Ensembl chr 1:203,277,344...203,300,177

G

capping actin protein of muscle Z-line subunit alpha 1

decreases expression

Simvastatin results in decreased expression of CAPZA1 protein

NCBI chr 2:192,319,696...192,364,755
Ensembl chr 2:192,319,702...192,364,480

G

capping actin protein of muscle Z-line subunit alpha 2

decreases expression

Simvastatin results in decreased expression of CAPZA2 protein

NCBI chr 4:45,978,142...46,014,032
Ensembl chr 4:45,977,807...46,013,864

G

caspase 1

decreases activity
multiple interactions

Simvastatin results in decreased activity of CASP1 protein
Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of CASP1 protein]]; Simvastatin inhibits the reaction [Acetic Acid results in increased expression of CASP1 protein]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of CASP1 protein]

PMID:16054375 PMID:30408459 PMID:35762198

NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383

G

caspase 12

multiple interactions

Simvastatin results in increased cleavage of and results in increased activity of CASP12 protein

NCBI chr 8:2,642,296...2,669,549
Ensembl chr 8:2,642,434...2,674,037

G

caspase 3

multiple interactions
increases cleavage
increases activity
decreases activity
increases expression

geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in increased activity of CASP3 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased activity of CASP3 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of CASP3 protein]; Simvastatin inhibits the reaction [APP protein alternative form results in decreased expression of CASP3 protein]; Simvastatin inhibits the reaction [APP protein alternative form results in increased activity of CASP3 protein]; Simvastatin inhibits the reaction [Coal Ash results in increased expression of CASP3 protein modified form]; Simvastatin inhibits the reaction [Homocysteine results in increased activity of CASP3 protein]; Simvastatin results in increased cleavage of and results in increased activity of CASP3 protein
Simvastatin results in increased cleavage of CASP3 protein
Simvastatin results in decreased activity of CASP3 protein
Simvastatin results in increased expression of CASP3 mRNA; Simvastatin results in increased expression of CASP3 protein
carvacrol inhibits the reaction [Simvastatin promotes the reaction [Poloxamer results in increased expression of CASP3 protein]]; farnesyl pyrophosphate inhibits the reaction [Simvastatin results in increased activity of CASP3 protein]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in increased activity of CASP3 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased activity of CASP3 protein]; Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in increased cleavage of CASP3 protein]]; PD 150606 inhibits the reaction [Simvastatin results in increased activity of CASP3 protein]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased cleavage of CASP3 protein]; Simvastatin inhibits the reaction [Glucose results in increased cleavage of CASP3 protein]; Simvastatin inhibits the reaction [Monocrotaline results in increased expression of CASP3 mRNA]; Simvastatin promotes the reaction [Poloxamer results in increased expression of CASP3 protein]; Simvastatin results in decreased expression of and results in decreased activity of CASP3 protein; Simvastatin results in increased cleavage of and results in increased activity of CASP3 protein; Verapamil inhibits the reaction [Simvastatin results in increased activity of CASP3 protein]
[Glucose deficiency co-treated with Simvastatin] results in increased cleavage of CASP3 protein; [Lipopolysaccharides co-treated with Simvastatin] results in increased activity of CASP3 protein; Acetylcysteine inhibits the reaction [Simvastatin results in increased activity of CASP3 protein]; IGF1 protein inhibits the reaction [Simvastatin results in increased cleavage of CASP3 protein]; zinc protoporphyrin inhibits the reaction [[Glucose deficiency co-treated with Simvastatin] results in increased cleavage of CASP3 protein]

PMID:11868908 PMID:12557325 PMID:12962723 PMID:14527821 PMID:15200425 More...

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 6

multiple interactions

Simvastatin results in increased cleavage of and results in increased activity of CASP6 protein

NCBI chr 2:218,466,063...218,478,503
Ensembl chr 2:218,466,076...218,478,502

G

caspase 7

multiple interactions
increases activity

Mevalonic Acid inhibits the reaction [Simvastatin results in increased activity of CASP7 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased cleavage of CASP7 protein]; Simvastatin results in increased cleavage of and results in increased activity of CASP7 protein

PMID:19253821 PMID:20045437 PMID:20427495

NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729

G

caspase 8

increases activity
multiple interactions
increases cleavage

Simvastatin results in increased activity of CASP8 protein
Simvastatin results in increased cleavage of and results in increased activity of CASP8 protein
Simvastatin results in increased cleavage of CASP8 protein
Acetylcysteine inhibits the reaction [Simvastatin results in increased activity of CASP8 protein]

PMID:12962723 PMID:15705602 PMID:20464445 PMID:20883752 PMID:21910007

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

caspase 9

multiple interactions
increases activity
decreases activity
increases cleavage

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin results in decreased activity of CASP9 protein]; DIABLO protein promotes the reaction [Simvastatin results in increased activity of CASP9 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased cleavage of CASP9 protein]; Simvastatin results in increased cleavage of and results in increased activity of CASP9 protein

PMID:12438947 PMID:12962723 PMID:15705602 PMID:16470222 PMID:19253821 More...

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

catalase

decreases expression
multiple interactions
increases activity

Simvastatin results in decreased expression of CAT mRNA
carvacrol promotes the reaction [Simvastatin inhibits the reaction [Poloxamer results in decreased activity of CAT protein]]; Simvastatin inhibits the reaction [Diazepam results in decreased activity of CAT protein]; Simvastatin inhibits the reaction [Poloxamer results in decreased activity of CAT protein]
Simvastatin results in increased activity of CAT protein

PMID:17479860 PMID:20883752 PMID:27111380 PMID:29071762

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

caveolin 1

multiple interactions
decreases expression

Simvastatin inhibits the reaction [Glucose results in decreased expression of CAV1 mRNA]
Simvastatin inhibits the reaction [[Semaxinib co-treated with Oxygen deficiency] results in decreased expression of CAV1 protein]
Simvastatin results in decreased expression of CAV1 protein
Simvastatin promotes the reaction [[APOA4 protein co-treated with CBS protein] affects the expression of CAV1 protein]

PMID:16698853 PMID:18224302 PMID:19816600

NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705

G

caveolin 2

multiple interactions

Simvastatin inhibits the reaction [[Semaxinib co-treated with Oxygen deficiency] results in decreased expression of CAV2 protein]

NCBI chr 4:45,616,766...45,624,144
Ensembl chr 4:45,616,712...45,624,244

G

cystathionine beta synthase

multiple interactions

Simvastatin inhibits the reaction [[APOA4 protein co-treated with CBS protein] affects the abundance of Nitrogen Compounds]; Simvastatin promotes the reaction [[APOA4 protein co-treated with CBS protein] affects the expression of CAV1 protein]

NCBI chr20:9,708,089...9,732,623
Ensembl chr20:9,708,090...9,732,764

G

C-C motif chemokine ligand 2

multiple interactions
decreases expression
affects expression
decreases response to substance

[Simvastatin co-treated with Ramipril] results in decreased expression of CCL2 protein; [Valsartan co-treated with Simvastatin] inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased expression of CCL2 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCL2 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of CCL2 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CCL2 mRNA]; Simvastatin inhibits the reaction [AGT protein results in increased expression of CCL2 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCL2 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased secretion of CCL2 protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]; Simvastatin inhibits the reaction [TNF results in increased expression of CCL2 mRNA]; Simvastatin inhibits the reaction [TNF results in increased secretion of CCL2 protein]; Simvastatin results in decreased expression of and results in decreased secretion of CCL2 protein
Simvastatin affects the expression of CCL2 mRNA
Simvastatin results in decreased expression of CCL2 mRNA; Simvastatin results in decreased expression of CCL2 protein
Simvastatin results in decreased susceptibility to CCL2 protein

PMID:12117737 PMID:12818400 PMID:15184351 PMID:15781755 PMID:15824212 More...

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 20

decreases expression

Simvastatin results in decreased expression of CCL20 mRNA

NCBI chr 9:84,389,031...84,391,629
Ensembl chr 9:84,388,904...84,391,629

G

C-C motif chemokine ligand 3

multiple interactions
decreases expression

Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCL3 mRNA]]; Simvastatin inhibits the reaction [IFNG results in increased secretion of CCL3 mRNA]
Simvastatin results in decreased expression of CCL3 mRNA

PMID:16321392 PMID:16414398

NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938

G

C-C motif chemokine ligand 4

multiple interactions

Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCL4 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of CCL4 mRNA]]; Simvastatin inhibits the reaction [IFNG results in increased secretion of CCL4 mRNA]; Simvastatin inhibits the reaction [TNF results in increased secretion of CCL4 mRNA]

NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231

G

C-C motif chemokine ligand 5

increases expression
decreases expression

Simvastatin results in increased expression of CCL5 mRNA
Simvastatin results in decreased expression of CCL5 protein
Simvastatin results in decreased expression of CCL5 mRNA

PMID:17112859 PMID:17183729 PMID:17449418

NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377

G

cellular communication network factor 1

multiple interactions
decreases expression

Simvastatin inhibits the reaction [CCN1 results in increased expression of IL1B]; Simvastatin inhibits the reaction [CCN1 results in increased expression of OSM]; Simvastatin inhibits the reaction [CCN1 results in increased expression of TNF]; Simvastatin inhibits the reaction [OSM results in increased expression of CCN1 mRNA]
Simvastatin results in decreased expression of CCN1 mRNA

PMID:17428261 PMID:20191585

NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484

G

cellular communication network factor 2

multiple interactions
decreases expression

geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TGFB1 results in increased expression of CCN2 mRNA]]; Simvastatin inhibits the reaction [TGFB1 results in increased expression of CCN2 mRNA]; Simvastatin inhibits the reaction [TGFB1 results in increased expression of CCN2 protein]
Simvastatin results in decreased expression of CCN2 mRNA; Simvastatin results in decreased expression of CCN2 protein
Simvastatin inhibits the reaction [lysophosphatidic acid results in increased expression of CCN2 protein]
Simvastatin inhibits the reaction [Bleomycin results in increased expression of CCN2 mRNA]; Simvastatin inhibits the reaction [Bleomycin results in increased expression of CCN2 protein]

PMID:15200425 PMID:15298857 PMID:15677772 PMID:19080365 PMID:19099753 More...

NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734

G

cyclin A2

decreases expression
multiple interactions

Simvastatin results in decreased expression of CCNA2 mRNA
Simvastatin results in decreased expression of CCNA2 protein
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of CCNA2 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CCNA2 protein]

PMID:17428261 PMID:26577051

NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577

G

cyclin D1

multiple interactions
decreases expression

Simvastatin inhibits the reaction [TNF protein results in increased expression of CCND1 protein]
Simvastatin results in decreased expression of CCND1 mRNA; Simvastatin results in decreased expression of CCND1 protein

PMID:17277159 PMID:17428261 PMID:20878096

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cyclin E1

multiple interactions
decreases expression

geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of CCNE1 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CCNE1 protein]

NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101

G

C-C motif chemokine receptor 1

multiple interactions
decreases expression

Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCR1 mRNA]]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCR1 mRNA]
Simvastatin results in decreased expression of CCR1 mRNA

PMID:16321392 PMID:16414398

NCBI chr 8:123,556,286...123,561,841

G

C-C motif chemokine receptor 2

multiple interactions
decreases expression

[2-chloro-5-nitrobenzanilide binds to and results in decreased activity of PPARG protein] inhibits the reaction [Simvastatin results in decreased expression of CCR2 mRNA]; [2-chloro-5-nitrobenzanilide binds to and results in decreased activity of PPARG protein] inhibits the reaction [Simvastatin results in decreased expression of CCR2 protein]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCR2 mRNA]]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCR2 mRNA]
Simvastatin results in decreased expression of CCR2 mRNA; Simvastatin results in decreased expression of CCR2 protein

PMID:15781755 PMID:16321392 PMID:16414398 PMID:16781696 PMID:17449418

NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100

G

C-C motif chemokine receptor 4

multiple interactions

Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of CCR4 mRNA]]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCR4 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of CCR4 mRNA]

NCBI chr 8:114,176,291...114,182,033
Ensembl chr 8:114,176,974...114,178,056

G

C-C motif chemokine receptor 5

multiple interactions
decreases expression

Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCR5 mRNA]]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCR5 mRNA]
Simvastatin results in decreased expression of CCR5 protein
Simvastatin results in decreased expression of CCR5 mRNA

PMID:16321392 PMID:17112859 PMID:17449418

NCBI chr 8:123,752,423...123,757,538
Ensembl chr 8:123,752,325...123,759,260

G

CD14 molecule

decreases expression

Simvastatin results in decreased expression of CD14 mRNA

NCBI chr18:28,335,522...28,337,383
Ensembl chr18:28,335,340...28,337,261

G

CD151 molecule (Raph blood group)

decreases expression

Simvastatin results in decreased expression of CD151 mRNA

NCBI chr 1:196,564,744...196,568,753
Ensembl chr 1:196,565,181...196,568,753

G

CD24 molecule

increases expression

Simvastatin results in increased expression of CD24 mRNA

NCBI chr20:47,074,353...47,079,662
Ensembl chr20:47,073,512...47,079,662

G

CD27 molecule

decreases expression

Simvastatin results in decreased expression of CD27 mRNA

NCBI chr 4:158,030,700...158,035,862
Ensembl chr 4:158,030,703...158,035,592

G

CD2-associated protein

increases expression

Simvastatin results in increased expression of CD2AP mRNA

NCBI chr 9:18,086,744...18,182,744
Ensembl chr 9:18,086,984...18,182,199

G

CD40 molecule

decreases expression
multiple interactions

Simvastatin results in decreased expression of CD40 protein
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 protein]]; Simvastatin inhibits the reaction [IFNG promotes the reaction [STAT1 binds to CD40 promoter]]; Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 protein]; Simvastatin promotes the reaction [IFNG promotes the reaction [RELA binds to CD40 promoter]]

PMID:16387846 PMID:17169357 PMID:17507688

NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534

G

CD40 ligand

decreases expression
multiple interactions
increases expression

Simvastatin results in decreased expression of CD40LG protein; Simvastatin results in decreased expression of CD40LG protein modified form
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CD40LG results in increased expression of VCAM1 mRNA]]; Simvastatin inhibits the reaction [CD40LG results in increased expression of VCAM1 mRNA]
Simvastatin results in increased expression of CD40LG protein

PMID:17169357 PMID:18269829 PMID:21330348

NCBI chr X:135,127,052...135,138,768
Ensembl chr X:135,126,969...135,138,306

G

CD44 molecule

multiple interactions
decreases expression

Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CD44 protein]; Simvastatin promotes the reaction [TP53 protein binds to CD44 promoter]
Simvastatin results in decreased expression of CD44 mRNA; Simvastatin results in decreased expression of CD44 protein

NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620

G

Cd80 molecule

decreases expression

Simvastatin results in decreased expression of CD80 mRNA

NCBI chr11:62,254,543...62,293,414
Ensembl chr11:62,254,624...62,292,030

G

CD83 molecule

decreases expression

Simvastatin results in decreased expression of CD83 protein

NCBI chr17:20,887,309...20,907,009
Ensembl chr17:20,887,309...20,907,083

G

CD86 molecule

decreases expression

Simvastatin results in decreased expression of CD86 protein

NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818

G

cell division cycle 25B

affects expression

Simvastatin affects the expression of CDC25B mRNA; Simvastatin affects the expression of CDC25B protein

NCBI chr 3:118,407,127...118,417,272
Ensembl chr 3:118,407,128...118,417,272

G

cell division cycle 42

decreases activity

Simvastatin results in decreased activity of CDC42 protein

NCBI chr 5:149,555,069...149,593,239
Ensembl chr 5:149,553,724...149,593,111

G

cell division cycle 45

decreases expression

Simvastatin results in decreased expression of CDC45 mRNA

NCBI chr11:82,185,427...82,210,630
Ensembl chr11:82,185,473...82,210,619

G

cell division cycle 6

decreases expression

Simvastatin results in decreased expression of CDC6 mRNA

NCBI chr10:83,864,189...83,878,011
Ensembl chr10:83,864,638...83,878,011

G

cadherin 5

increases expression

Simvastatin results in increased expression of CDH5 mRNA; Simvastatin results in increased expression of CDH5 protein

NCBI chr19:815,415...854,478
Ensembl chr19:815,411...854,368

G

cyclin-dependent kinase 1

decreases expression
multiple interactions

Simvastatin results in decreased expression of CDK1 mRNA; Simvastatin results in decreased expression of CDK1 protein
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of CDK1 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CDK1 protein]

PMID:17428261 PMID:20878096 PMID:26577051

NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408

G

cyclin dependent kinase 2

multiple interactions
decreases expression
decreases activity

[Simvastatin results in decreased degradation of CDKN1A protein] which results in decreased activity of CDK2 protein; [Simvastatin results in decreased degradation of CDKN1B protein] which results in decreased activity of CDK2 protein
Simvastatin results in decreased expression of CDK2 protein
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of CDK2 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CDK2 protein]
Simvastatin results in decreased activity of CDK2 protein

PMID:10412745 PMID:17928568 PMID:18804536 PMID:20878096 PMID:26577051

NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403

G

cyclin-dependent kinase 4

decreases expression
decreases activity

Simvastatin results in decreased expression of CDK4 protein
Simvastatin results in decreased activity of CDK4 protein

PMID:18804536 PMID:20878096

NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403

G

cyclin-dependent kinase 5

increases expression

Simvastatin results in increased expression of CDK5

NCBI chr 4:10,754,682...10,760,110
Ensembl chr 4:10,754,687...10,760,112

G

cyclin-dependent kinase inhibitor 1A

multiple interactions
increases expression

[Simvastatin results in decreased degradation of CDKN1A protein] which results in decreased activity of CDK2 protein; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in increased expression of CDKN1A protein]; Simvastatin inhibits the reaction [Fluorouracil results in decreased degradation of CDKN1A protein]
Simvastatin results in increased expression of CDKN1A mRNA; Simvastatin results in increased expression of CDKN1A protein

PMID:15625077 PMID:17428261 PMID:17928568 PMID:18337644 PMID:18625202 More...

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 1B

multiple interactions
increases expression

[Simvastatin results in decreased degradation of CDKN1B protein] which results in decreased activity of CDK2 protein
Simvastatin results in increased expression of CDKN1B mRNA; Simvastatin results in increased expression of CDKN1B protein

PMID:12963647 PMID:17428261 PMID:17928568 PMID:18337644 PMID:18804536 More...

NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982

G

cyclin-dependent kinase inhibitor 1C

increases expression

Simvastatin results in increased expression of CDKN1C mRNA

NCBI chr 1:198,655,394...198,658,097
Ensembl chr 1:198,655,407...198,658,048

G

cyclin-dependent kinase inhibitor 2A

increases expression

Simvastatin results in increased expression of CDKN2A protein

NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149

G

cyclin dependent kinase inhibitor 2D

increases expression

Simvastatin results in increased expression of CDKN2D mRNA; Simvastatin results in increased expression of CDKN2D protein

NCBI chr 8:19,831,874...19,834,640
Ensembl chr 8:19,831,866...19,834,674

G

chromatin licensing and DNA replication factor 1

decreases expression

Simvastatin results in decreased expression of CDT1 mRNA

NCBI chr19:50,620,713...50,625,659
Ensembl chr19:50,620,713...50,625,659

G

CCAAT/enhancer binding protein zeta

multiple interactions

Simvastatin inhibits the reaction [CEBPZ binds to COL1A1 promoter]

NCBI chr 6:16,119,871...16,137,600
Ensembl chr 6:16,119,872...16,137,600

G

carboxylesterase 1D

multiple interactions

Simvastatin affects the reaction [Dietary Fats affects the expression of CES1 mRNA]; Simvastatin affects the reaction [Dietary Fats affects the expression of CES1 protein]
Simvastatin inhibits the reaction [CES1 protein results in increased hydrolysis of remdesivir]

PMID:33383043 PMID:34774545

NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035

G

CASP8 and FADD-like apoptosis regulator

multiple interactions
increases expression
decreases expression

Simvastatin inhibits the reaction [TNF protein results in increased expression of CFLAR protein]
Simvastatin results in increased expression of CFLAR mRNA; Simvastatin results in increased expression of CFLAR protein
Simvastatin results in decreased expression of CFLAR protein; Simvastatin results in decreased expression of CFLAR protein alternative form

PMID:17277159 PMID:18521906 PMID:19262002 PMID:21910007

NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034

G

CF transmembrane conductance regulator

multiple interactions

Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of CFTR mRNA]; Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of CFTR protein]

NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756

G

choline O-acetyltransferase

multiple interactions

Simvastatin inhibits the reaction [ITGAL affects the susceptibility to and affects the activity of CHAT protein]; Simvastatin inhibits the reaction [ITGAL affects the susceptibility to and affects the expression of CHAT mRNA]

NCBI chr16:7,657,362...7,717,093
Ensembl chr16:7,657,362...7,717,093

G

cholinergic receptor, muscarinic 5

multiple interactions

Simvastatin inhibits the reaction [ITGAL affects the susceptibility to and affects the expression of CHRM5 mRNA]

NCBI chr 3:99,284,846...99,337,252
Ensembl chr 3:99,284,846...99,337,252

G

component of inhibitor of nuclear factor kappa B kinase complex

multiple interactions
increases expression
increases phosphorylation

artemisinin inhibits the reaction [Simvastatin results in increased phosphorylation of CHUK protein]; parthenolide inhibits the reaction [Simvastatin results in increased phosphorylation of CHUK protein]; Simvastatin promotes the reaction [Doxorubicin results in increased phosphorylation of CHUK protein]
Simvastatin results in increased expression of CHUK mRNA

PMID:18463201 PMID:19262002

NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065

G

class II, major histocompatibility complex, transactivator

multiple interactions

Simvastatin inhibits the reaction [IFNG results in increased expression of CIITA protein]

NCBI chr10:5,139,947...5,187,493
Ensembl chr10:5,140,178...5,187,440

G

creatine kinase, M-type

multiple interactions
increases secretion
decreases expression

[Clarithromycin co-treated with Simvastatin] results in increased expression of CKM protein
Simvastatin results in increased secretion of CKM protein
carvacrol inhibits the reaction [Simvastatin results in increased secretion of CKM protein]; Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of CKM protein]]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of CKM protein]
Simvastatin results in decreased expression of CKM protein

PMID:8611662 PMID:19252767 PMID:29071762 PMID:35762198

NCBI chr 1:79,061,390...79,071,721
Ensembl chr 1:79,061,456...79,071,720

G

chloride voltage-gated channel 3

multiple interactions
decreases expression

Simvastatin inhibits the reaction [EDN1 protein results in increased expression of CLCN3 protein]
Simvastatin results in decreased expression of CLCN3 protein

NCBI chr16:29,127,152...29,200,133
Ensembl chr16:29,127,419...29,200,119

G

claudin 18

multiple interactions

Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of CLDN18 mRNA]; Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of CLDN18 protein]

NCBI chr 8:100,246,499...100,265,797
Ensembl chr 8:100,247,633...100,273,351

G

claudin 4

multiple interactions

Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of CLDN4 mRNA]; Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of CLDN4 protein]

NCBI chr12:21,751,638...21,753,436
Ensembl chr12:21,751,331...21,753,436

G

collagen type XI alpha 1 chain

increases expression

Simvastatin results in increased expression of COL11A1 mRNA

NCBI chr 2:201,820,715...202,013,853
Ensembl chr 2:201,820,715...202,013,853

G

collagen type XII alpha 1 chain

increases expression

Simvastatin results in increased expression of COL12A1 mRNA

NCBI chr 8:80,547,592...80,665,665
Ensembl chr 8:80,547,593...80,665,686

G

collagen type XIII alpha 1 chain

decreases response to substance

COL13A1 SNP results in decreased susceptibility to Simvastatin

NCBI chr20:29,783,965...29,924,116
Ensembl chr20:29,783,965...29,924,032

G

collagen type I alpha 1 chain

multiple interactions
increases expression
decreases expression

geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of COL1A1 mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of COL1A1 mRNA]; Simvastatin inhibits the reaction [CEBPZ binds to COL1A1 promoter]; Simvastatin inhibits the reaction [SP1 binds to COL1A1 promoter]
Simvastatin results in increased expression of COL1A1 mRNA

PMID:10412775 PMID:14973129 PMID:16274305 PMID:16575855 PMID:17252541 More...

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

collagen type II alpha 1 chain

multiple interactions
increases expression

Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of COL2A1 mRNA]; NOG inhibits the reaction [Simvastatin results in increased expression of COL2A1 mRNA]

PMID:18628692 PMID:19912653

NCBI chr 7:129,098,489...129,127,560
Ensembl chr 7:129,098,786...129,127,546

G

collagen type III alpha 1 chain

increases expression
decreases expression

Simvastatin results in increased expression of COL3A1 mRNA
Simvastatin results in decreased expression of COL3A1 mRNA

PMID:10412775 PMID:16274305 PMID:16414398 PMID:17183729

NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547

G

collagen type IV alpha 1 chain

decreases expression

Simvastatin results in decreased expression of COL4A1 mRNA

NCBI chr16:78,183,533...78,294,412
Ensembl chr16:78,183,533...78,294,412

G

collagen type V alpha 1 chain

increases expression

Simvastatin results in increased expression of COL5A1 mRNA

NCBI chr 3:11,208,429...11,356,715
Ensembl chr 3:11,208,512...11,354,588

G

collagen type VI alpha 2 chain

increases expression

Simvastatin results in increased expression of COL6A2 mRNA

NCBI chr20:12,021,676...12,049,425
Ensembl chr20:12,021,767...12,057,564

G

collagen type VII alpha 1 chain

increases expression

Simvastatin results in increased expression of COL7A1 mRNA

NCBI chr 8:109,604,877...109,637,249
Ensembl chr 8:109,604,861...109,637,252

G

coronin 1A

decreases expression

Simvastatin results in decreased expression of CORO1A protein

NCBI chr 1:181,295,561...181,300,566
Ensembl chr 1:181,295,562...181,300,534

G

cAMP responsive element binding protein 1

multiple interactions

Simvastatin inhibits the reaction [OSM results in increased phosphorylation of CREB1 protein]

NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816

G

C-reactive protein

decreases expression
multiple interactions

Simvastatin results in decreased expression of CRP protein
[Ezetimibe co-treated with Simvastatin] results in decreased expression of CRP protein; [Simvastatin co-treated with Ezetimibe] promotes the reaction [Niacin results in decreased expression of CRP protein]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [CRP results in increased expression of RETN mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [CRP results in increased secretion of RETN protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CRP results in increased expression of RETN mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CRP results in increased secretion of RETN protein]]; Simvastatin inhibits the reaction [[Ethinyl Estradiol co-treated with Desogestrel] results in increased expression of CRP protein]; Simvastatin inhibits the reaction [CRP results in increased expression of RETN mRNA]; Simvastatin inhibits the reaction [CRP results in increased secretion of RETN protein]; Simvastatin inhibits the reaction [ethinyl estradiol-desogestrel combination results in increased expression of CRP protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of CRP protein]

PMID:15184351 PMID:15824212 PMID:17105841 PMID:18023360 PMID:18420099 More...

NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178

G

citrate synthase

multiple interactions
increases activity

[Simvastatin co-treated with Lipopolysaccharides] results in increased activity of CS protein
Simvastatin results in increased activity of CS protein

NCBI chr 7:758,074...791,421
Ensembl chr 7:758,345...791,421

G

chondroitin sulfate proteoglycan 4

increases expression

Simvastatin results in increased expression of CSPG4 mRNA

NCBI chr 8:57,264,962...57,300,010
Ensembl chr 8:57,264,962...57,300,010

G

cardiotrophin 1

multiple interactions

Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK1 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK2 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of NPPA mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of STAT1 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of STAT3 protein]]; Simvastatin inhibits the reaction [CTF1 results in increased expression of AGT mRNA]; Simvastatin inhibits the reaction [CTF1 results in increased expression of FOS mRNA]; Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK1 protein]; Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK2 protein modified form]; Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK2 protein]; Simvastatin inhibits the reaction [CTF1 results in increased expression of NPPA mRNA]; Simvastatin inhibits the reaction [CTF1 results in increased expression of STAT1 protein]; Simvastatin inhibits the reaction [CTF1 results in increased expression of STAT3 protein modified form]; Simvastatin inhibits the reaction [CTF1 results in increased expression of STAT3 protein]; Simvastatin inhibits the reaction [CTF1 results in increased phosphorylation of JAK2 protein]; Simvastatin inhibits the reaction [CTF1 results in increased phosphorylation of STAT3 protein]

PMID:16534557 PMID:18400235 PMID:19100119

NCBI chr 1:182,328,035...182,336,346
Ensembl chr 1:182,328,090...182,333,335

G

cytotoxic T-lymphocyte-associated protein 4

decreases expression

Simvastatin results in decreased expression of CTLA4 mRNA

NCBI chr 9:62,318,874...62,325,978
Ensembl chr 9:62,319,312...62,324,963

G

catenin alpha-like 1

decreases expression

Simvastatin results in decreased expression of CTNNAL1 mRNA

NCBI chr 5:71,514,340...71,569,431
Ensembl chr 5:71,514,340...71,569,431

G

catenin beta 1

multiple interactions
increases expression

CTNNB1 mutant form inhibits the reaction [Simvastatin results in increased expression of BGLAP protein]; CTNNB1 mutant form inhibits the reaction [Simvastatin results in increased expression of SP7 protein]
Simvastatin results in increased expression of CTNNB1 protein
Simvastatin inhibits the reaction [Glucose results in decreased expression of CTNNB1 protein]

PMID:18004065 PMID:22058016

NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111

G

cathepsin L

increases expression

Simvastatin results in increased expression of CTSL mRNA

NCBI chr17:764,370...770,533
Ensembl chr17:764,309...770,548

G

cathepsin S

multiple interactions

Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in increased expression of CTSS mRNA]; Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in increased expression of CTSS protein]

NCBI chr 2:183,086,437...183,114,483
Ensembl chr 2:183,086,437...183,114,483

G

cortactin

affects localization
multiple interactions

Simvastatin affects the localization of CTTN protein
Simvastatin affects the reaction [F2 affects the localization of CTTN protein]

NCBI chr 1:199,599,710...199,635,254
Ensembl chr 1:199,599,710...199,635,164

G

C-X3-C motif chemokine receptor 1

decreases expression

Simvastatin results in decreased expression of CX3CR1 mRNA

NCBI chr 8:119,785,726...119,799,431
Ensembl chr 8:119,782,595...119,800,014

G

C-X-C motif chemokine ligand 10

multiple interactions
decreases expression

Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of CXCL10 mRNA]; Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of CXCL10 protein]
Simvastatin results in decreased expression of CXCL10 mRNA; Simvastatin results in decreased expression of CXCL10 protein

PMID:15187114 PMID:16414398 PMID:17449418 PMID:22305382

NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975

G

C-X-C motif chemokine ligand 12

increases expression

Simvastatin results in increased expression of CXCL12

NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168

G

C-X-C motif chemokine ligand 16

decreases expression

Simvastatin results in decreased expression of CXCL16 mRNA

NCBI chr10:55,166,721...55,171,316
Ensembl chr10:55,166,723...55,171,592

G

C-X-C motif chemokine ligand 2

decreases expression

Simvastatin results in decreased expression of CXCL2 mRNA; Simvastatin results in decreased expression of CXCL2 protein

PMID:21330348 PMID:21441352

NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075

G

C-X-C motif chemokine ligand 3

decreases expression

Simvastatin results in decreased expression of CXCL1 mRNA; Simvastatin results in decreased expression of CXCL1 protein

PMID:21330348 PMID:21441352

NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511

G

C-X-C motif chemokine receptor 2

decreases expression

Simvastatin results in decreased expression of CXCR2 mRNA

NCBI chr 9:75,729,493...75,735,868
Ensembl chr 9:75,729,115...75,739,425

G

C-X-C motif chemokine receptor 4

decreases expression
increases expression

Simvastatin results in decreased expression of CXCR4 mRNA
Simvastatin results in increased expression of CXCR4

PMID:16414398 PMID:19591934

NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883

G

cytochrome b-245 alpha chain

affects response to substance

CYBA gene SNP affects the susceptibility to Simvastatin

NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721

G

cytochrome b-245 beta chain

multiple interactions

Simvastatin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of CYBB protein]

NCBI chr X:13,358,101...13,392,570
Ensembl chr X:13,359,430...13,392,586

G

cytochrome P450, family 11, subfamily a, polypeptide 1

multiple interactions

[Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of CYP11A1 mRNA; [Simvastatin co-treated with resveratrol] results in decreased expression of CYP11A1 mRNA

PMID:24524197 PMID:25055962

NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338

G

cytochrome P450, family 11, subfamily b, polypeptide 2

multiple interactions

[Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of CYP11B1 mRNA